Stockwinners Market Radar for November 15, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:29 EST Tesla's Musk sells 148K shares of common stock, 786K shares as option expiry - In a regulatory filing, Tesla disclosed that it CEO Elon Musk sold 148.2K shares of common stock in a total transaction size of $150.5M and another 786K shares of common stock after option expiry in a $780M transaction size.

19:56 EST Biogen Head of Research Alfred Sandrock to retire - Biogen announced that Alfred Sandrock, Jr., M.D., Ph.D., Head of Research & Development, will retire from the company effective December 31, 2021. Priya Singhal, M.D., M.P.H., Head of Global Safety and Regulatory Sciences, also with oversight responsibility for Japan and China R&D, will assume Dr. Sandrock's duties as Head of Research & Development on an interim basis until a permanent successor is identified.

19:02 EST Twilio CEO buys 3.4K shares of common stock - In a regulatory filing, Twilio disclosed that its CEO Jeffrey Immelt bought 3.4K shares of common stock on November 11th in a total transaction size of $1.0M, boosting his stake by about 25%.

18:55 EST Tabula Rasa HealthCare CEO sells 200K shares of common stock - In a regulatory filing, Tabula Rasa HealthCare disclosed that its CEO Calvin Knowlton sold 200K shares of common stock on November 11th in a total transaction size of $2.77M, reducing his stake by about 17%.

18:14 EST HollyFrontier chairman Myers buys 20,000 common shares - In a regulatory filing, HollyFrontier chairman Franklin Myers disclosed the purchase of 20,000 common shares of the company on November 12 at a price of $34.56 per share.

17:54 EST Copa Holdings reports October traffic down 25.4% vs. October 2019 - Copa Holdings' October consolidated capacity, or ASMs, came in 22.8% lower than October 2019, while passenger traffic, or RPMs, decreased 25.4%, which resulted in a 82.0% load factor vs. 84.9% in October of 2019.

17:37 EST Consolidated Water expects an increase in PERC's bidding activity - "During the quarter, PERC continued to grow its recurring revenues by signing a five-year contract to provide operating and maintenance services for the wastewater plant of a gaming and live entertainment business in Southern California. New project opportunities for PERC, both sole-sourced and competitively bid, continue to be strong and include bids for two major projects that were submitted in the first nine months of this year," commented Consolidated Water CEO, Rick McTaggart. "We expect to hear whether PERC was selected for these projects by early next year. But based on this overall increased bidding activity that reflects strengthening market demand, we believe PERC's performance for 2022 will exceed this year as new water treatment projects come to market after the lull due to the pandemic. Near the end of October, the Cayman Islands government announced that the country will reopen its borders for nearly all vaccinated travelers this Saturday, November 20th. We see the reopening as a major step toward the reopening of hotels and resorts in Grand Cayman and expect a gradual return to normalcy for our retail water segment. The Bahamas remains open to tourism, and we are seeing increased marketing activity to tourists. We believe our strong balance sheet and liquidity enables us to ride out the continued adverse economic impacts of the pandemic, while enabling us to fund growth initiatives. We see the increase in PERC's bidding activity and the increased project activity in our markets as potential major catalysts for our growth in 2022 and thereafter."

17:25 EST Landsea Homes appoints Chris Porter as CFO - Landsea Homes announced that Chris Porter has been hired for the Company's position of CFO. Chris has more than 30 years of diverse experience in corporate finance in both public and private equity settings across multiple industries, including commercial real estate, senior housing, defense contracting and banking/finance sectors. In this new role, Chris will manage all financial matters for the Company. In 2013, Chris joined senior housing real estate developer Silverstone Healthcare Company, as President and CFO. He was instrumental in growing the company to include nine luxury developments, and was successful in raising approximately $1B in debt and equity. During his tenure, he also oversaw all accounting, reporting, finance, human resources, liquidity and asset management functions. Prior to Silverstone, Chris served as Vice President and Treasurer of Dyn-Corp International, responsible for its global Treasury, Risk Management, Liquidity and Investor Relations. Before that, Chris spent 10 years at Crescent Real Estate Equities, ending as Managing Director, in charge of capital markets, risk management, and treasury.

17:13 EST Riot Blockchain sees Q4 self-mining hash rate capacity of 8.6 EH/s - The company said, "By Q4 2022, Riot anticipates a total self-mining hash rate capacity of 8.6 EH/s, not including any expected incremental productivity gains from the Company's utilization of 200 MW of immersion-cooling infrastructure and assuming full deployment of approximately 90,150 Antminer ASICs. Approximately 95% of Riot's self-mining fleet will consist of the latest generation S19 series miner model. Upon full deployment, the Company's total self-mining fleet is expected to consume approximately 284 MW of energy. In addition to the Company's self-mining operations, Riot's Whinstone Facility hosts approximately 200 MW of institutional Bitcoin mining clients."

17:08 EST Alfi appoints Louis Almerini as interim CFO - ALFI announced that Louis A. Almerini, has been appointed by the Company's Board of Directors to serve as interim CFO, effective November 8. With over 30 years of experience as a financial executive, Almerini has a proven track record leading corporate finance and accounting control functions for multiple public companies and financial institutions. Almerini brings a wealth of finance and accounting experience having served in a number of key roles running integrated business, budgeting, forecasting, financial analysis, accounting, regulatory reporting and operations. Almerini is Managing Member of Louis Almerini CPA, which provides outsourced CFO, FINOP, accounting, and related consulting services to clients directly or under contact as independent contractor with CFO Financial Partners. Since 2016, he has served as CFO or Chief Compliance Officer for several registered broker-dealers, investment advisers, and other companies.

17:06 EST Axon jumps over 17% to $196 per share after Q3 earnings beat

17:03 EST Talos Energy, Freeport LNG to develop carbon capture project on Gulf Coast - Freeport LNG Development, L.P. and Talos Energy Inc. announced that the companies have executed a letter of intent to develop a carbon capture and sequestration project, the Freeport LNG CCS project, immediately adjacent to Freeport LNG's natural gas pretreatment facilities located near Freeport, Texas, on the Gulf Coast, approximately 60 miles southwest of Houston, Texas. The companies anticipate first injection could occur by year-end 2024. Talos will be the project manager and operator and will be joined by its partner, Storegga Geotechnologies Limited, the lead developer of the Acorn CCS project in the United Kingdom. The FLNG CCS project will utilize a Freeport LNG-owned geological sequestration site located less than half a mile from point of capture with up to a 30-year injection term and will permanently sequester CO2. The FLNG CCS project benefits from a dedicated source of CO2 and a secured injection site in close physical proximity and, therefore, has limited commercial barriers and a rapid execution timeline assuming efficient regulatory approval processes. Additionally, the site is located within 25 miles of up to an additional 15 million metric tonnes per annum of incremental CO2 emissions from major industrial sources, which offers the potential for expansion in the future. The FLNG CCS project is still subject to execution of definitive agreements.

16:54 EST Ackman's Pershing Square exits Agilent, boosts Chipotle in Q3 - William Ackman's Pershing Square Capital disclosed in an SEC filing its holdings as of September 30, 2021. The fund exited one position during the third quarter, namely Agilent (A). Pershing Square increased its stake in six holdings, including by size of previous position Chipotle (CMG), Hilton Worldwide (HLT), Lowe's (LOW), Domino's Pizza (PZZA), and Restaurant Brands (QSR). The fund's top holdings as of September 30, in order of size, were Lowe's, Chipotle, Hilton Worldwide, Restaurant Brands, and Howard Hughes (HHC).

16:52 EST Ellington Financial reports estimated book value per share at Oct. 31 of $18.35 - Ellington Financial announced its estimated book value per share of common stock of $18.35 as of October 31, 2021. This estimate includes the effect of the previously announced monthly dividend of 15c per share of common stock, payable on November 26, 2021 to holders of record on October 29, 2021, with an ex-dividend date of October 28, 2021.

16:46 EST ToughBuilt receives 180 day extension to regain compliance with Nasdaq - ToughBuilt announced that the company received a 180 calendar day extension from Nasdaq's Listing Qualification Department to meet Nasdaq's continuing listing requirements by maintaining a minimum bid price per share of $1.00 for a minimum of 10 consecutive trading days. The company now has until May 14, 2022 to meet Nasdaq's minimum bid requirement. This current notification from Nasdaq has no immediate effect on the listing or trading of the Company's common stock, which will continue to trade on the Nasdaq Capital Market.

16:43 EST Amerant Bancorp shareholders approve clean-up merger - Amerant Bancorp announced that its shareholders approved a clean-up merger pursuant to which a subsidiary of the company will merge with and into the company. The Merger will simplify Amerant's capital structure by automatically converting shares of the company's Class B common stock into the company's shares of Class A common stock.Under the terms of the Merger, each outstanding share of Class B common stock will be automatically converted to 0.95 of a share of Class A common stock without any action on the part of the holders of Class B common stock; however, to the extent any shareholder, together with its affiliates, would own more than 8.9% of the outstanding shares of Class A common stock following the Merger, such holder's shares of Class A common stock or Class B common stock, as the case may be, will be converted into shares of a new class of Non-Voting Class A common stock, solely with respect to holdings that would be in excess of the 8.9% limit. The company currently intends the Merger to be effective on Thursday November 18th at 12:01 a.m. Eastern Time. Following the completion of the Merger, only the Company's shares of Class A common stock will trade on the NASDAQ under the symbol "AMTB". The Company expects that Wednesday November 17, 2021 will be the last day of trading of its shares of Class B common stock on the NASDAQ. "We are pleased to announce that our Class A and Class B shareholders were supportive of the view held by our Board and management regarding the benefits of having a single class of publicly traded common equity" stated Jerry Plush, Vice Chairman and CEO. "We can now focus on seeking alternatives to reduce our total cost of capital by optimizing its composition and by evaluating other ways to increase returns to our shareholders."

16:42 EST Citizens Financial completes acquisition of JMP Group - Citizens Financial Group announced that it has completed its acquisition of JMP Group LLC. JMP, which was founded in 1999 and is headquartered in San Francisco, will operate as a wholly-owned subsidiary of Citizens.

16:38 EST Appaloosa takes stake in Walmart, exits position in Netflix - Appaloosa disclosed in an SEC filing its holdings as of September 30, 2021. Appaloosa's three new buys during the third quarter included, by size of position, Alight (ALIT), Walmart (WMT), and Ovintiv (OVV). Appaloosa exited six positions during the quarter, including by size of previous position, Emerson Electric (EMR), Netflix (NFLX), BP (BP), and Royal Dutch Shell (RDS.A, RDS.B). Appaloosa increased its stake in eleven holdings, including by size of previous position, Macy's (M), Goodyear Tire & Rubber (GT), EQT Corp (EQT), Antero Resources (AR), and Alphabet Class C (GOOG). Appaloosa reduced its stake in 27 holdings, including by size of previous position, Micron (MU), Amazon (AMZN), Alibaba (BABA), PG&E (PCG), and Meta Platforms (FB). Appaloosa's top holdings as of September 30, in order of size, were Alphabet Class C, Meta Platforms, T-Mobile (TMUS), Amazon, and Occidental Petroleum (OXY).

16:37 EST Berkhire Hathaway buys Royalty Pharma, exits Merck in Q3 - Warren Buffett's Berkshire Hathaway (BRK.A) disclosed in an SEC filing its holdings as of September 30, 2021. The fund's two new buys during the third quarter included Royalty Pharma Class A (RPRX) and Floor & Decor (FND). Berkshire exited three holdings during the quarter, including by size of previous position Merck (MRK), Liberty Global Class C (LBTYK), and Organon (OGN). The fund increased its stake in one holding, namely Chevron (CVX). Berkshire reduced its stake in seven holdings, including by size of previous position AbbVie (ABBV), Charter (CHTR), Bristol-Myers (BMY), Visa (V), and Mastercard (MA). The fund's top holdings as of September 30, in order of size, were Apple (AAPL), Bank of America (BAC), American Express (AXP), Coca-Cola (KO), and Kraft Heinz (KHC).

16:34 EST Cboe Global Markets to acquire Aequitas Innovations for undisclosed amount - Cboe Global Markets announced it has entered into a definitive agreement to acquire Aequitas Innovations, more commonly known as NEO, a fintech organization that comprises of a fully registered Tier-1 Canadian securities exchange with a diverse product and services set ranging from corporate listings to cash equity trading. Ownership of NEO will help allow Cboe to provide a more fulsome Canadian equities offering, operating the NEO Exchange, a national securities exchange with trading, listings and other services, in addition to MATCHNow, the alternative trading system acquired by Cboe in 2020. The transaction, which Cboe plans to fund with cash on hand, supplemented by increased debt, if needed, is expected to close in the first half of 2022, subject to regulatory review and other customary closing conditions. Terms of the deal were not disclosed, however, the company noted that the purchase price is not material from a financial perspective and expects it to be nominally accretive. Legal advisors to Cboe Global Markets on the transaction are Blake, Cassels & Graydon LLP, with TD Securities serving as financial advisor.

16:34 EST KULR Technology reports Q3 EPS (1c), three estimates (2c) - Reports Q3 revenue $600,921, three estimates $600,000. On September 30, 2021, the company reported cash balances of $11M compared with $8.9M on December 31, 2020. KULR received approximately $6.5M of cash in the months of October 2021 and November 2021 from the exercise of warrants to purchase an aggregate of 2,600,000 shares. "This funding leaves KULR well positioned to expand operations, support new business, and fund ongoing product development initiatives despite facing macro-economic headwinds," the company said.

16:32 EST Vintage Wine Estates announces the acquisition ACE Cider - Vintage Wine Estates announced the acquisition of ACE Cider, The California Cider Company, which is expected to close November 16, 2021. "This strategic acquisition adds an innovative product line to our RTD, ready-to-drink, category and brings us access to a significant new sales channel for distribution, through which we expect we can push many of our brands," commented Pat Roney, VWE CEO. "ACE is an excellent complement to our wine portfolio and its products are distributed through the beer channel which provides a new growth opportunity for all of our RTD products. Importantly, this provides another platform from which we can expand by executing our strategy of consolidating highly fragmented offerings where we can leverage our production and marketing expertise to gain market share, capture more customers and increase volume."

16:32 EST Advance Auto Parts reports Q3 SSS up 3.1%

16:31 EST Farmland Partners announces acquisition of Murray Wise Associates LLC - Farmland Partners announced that it has acquired 100% of the equity interests in Murray Wise Associates LLC. The acquisition creates an unparalleled platform for farmland investing, including publicly traded equity, private asset management, individual farm purchases and individual farm management, and increases FPI's total farmland owned and/or managed by approximately 16,700 acres, the company said in a statement. The purchase price of MWA is $5M in cash and approximately $3M in FPI common stock. The acquisition includes approximately $3.8M in net current assets. In addition, FPI has entered into an incentive compensation arrangement for up to $3M in FPI common stock for the benefit of key current and prospective employees, the receipt of which is tied to achieving certain profitability and AUM objectives within three years after the closing.

16:26 EST JetBlue says new infrastructure bill 'enables meaningful enhancements' - JetBlue issued the following statement regarding the bipartisan Infrastructure Investment and Jobs Act: "JetBlue welcomes President Biden's signing of the bipartisan Infrastructure Investment and Jobs Act today. This legislation positions our nation to manage the challenges of climate change, a long-held priority for JetBlue as we have committed to achieve net zero carbon emissions by 2040. We are particularly excited about the bill's aviation investments including $25 billion for airports and its focus on bolstering aviation workforce diversity, another JetBlue priority." JetBlue CEO Robin Hayes, who attended the White House signing ceremony, added: "This legislation enables meaningful enhancements to our nation's roads, bridges and railways and will make travel safer, greener, and more equitable in all communities. Congratulations to President Biden and Congressional leaders - particularly JetBlue's home-state Senator Majority Leader Schumer - on this accomplishment."

16:21 EST Southwest Gas responds to director nominations from Carl Icahn - Southwest Gas Holdings, Inc. (SWX) confirmed that Icahn Enterprises LP (IEP) has provided notice of its intent to nominate 10 candidates to stand for election to take control of the company's Board of Directors at the company's 2022 Annual Meeting of Stockholders, the date of which has not yet been determined. The company issued the following statement regarding Icahn's director nominations: "Under the Board's oversight, we have created a company that is poised for further value creation across each of its businesses and the Company as a whole. Icahn's nomination of the Icahn slate follows the Board's rejection of Icahn's unsolicited, inadequate, structurally coercive, highly conditional and illusory tender offer to acquire the outstanding shares of the Company. The nomination of the Icahn slate is the latest step in Icahn's efforts to take control of Southwest Gas without paying a control premium to Southwest Gas stockholders and otherwise pursue his self-serving agenda. The Board values constructive dialogue with its investors with the mutual goal of enhancing value for all stakeholders - including for our local communities in partnership with our regulators in each of our three state commissions. As we do with all stockholders, members of the Company's management team have engaged directly with Icahn to hear his views and share ours. In these conversations, Icahn has criticized the pending Questar Pipelines acquisition and pressured Southwest Gas to pursue different alternatives for financing the acquisition - some of which treat Icahn differently than other stockholders... the Icahn slate has been assembled with one goal in mind-to facilitate Icahn's effort to take control of Southwest Gas without paying a control premium."

16:20 EST Oneok to complete announced natural gas infrastructure projects - ONEOK announced plans to complete previously announced natural gas and natural gas liquids, or NGL, infrastructure projects, including Demicks Lake III, a 200 million cubic feet per day, or MMcf/d, natural gas processing facility in the Williston Basin. MB-5, a 125,000-barrel per day, or bpd, NGL fractionator in Mont Belvieu, Texas. The remaining capital investment necessary to complete these projects is significantly less than building greenfield facilities, and will provide needed capacity at an attractive return on invested capital.

16:20 EST Archaea Energy signs 21-year RNG pact with Northwest Natural Gas - Archaea Energy Inc. (LFG) announced that its subsidiary Archaea Holdings, LLC has entered into a long-term RNG purchase and sale agreement with Northwest Natural Gas Company, a subsidiary of NW Natural Holdings (NWN). NW Natural provides natural gas service to approximately 2.5M people in Oregon and Southwest Washington. Under the agreement, NW Natural will purchase the environmental attributes generated by Archaea related to up to one million MMBtu of RNG annually from its portfolio of RNG production facilities for a fixed fee for a period of 21 years. The agreement will commence in early 2022, with the full annual quantity beginning in 2025. The RNG produced by Archaea for this long-term partnership is expected to have a positive impact through avoided methane emissions at U.S. landfills and displacement of conventional natural gas. "We are pleased to partner with NW Natural and look forward to our multi-decade business relationship," said Nick Stork, Archaea co-founder and CEO. "This agreement, our first with a U.S. utility, is a testament to the strength of our commercial offerings and highlights our ability to help utilities provide lower carbon options to their customers and achieve their sustainability goals."

16:18 EST Rocket Lab to acquire Planetary Systems Corporation for $42M - Rocket Lab USA announced it has signed a definitive agreement to acquire Planetary Systems Corporation, a Maryland-based spacecraft separation systems company, for $42M in cash and 1,720,841 shares of the company's common stock, plus the potential for an additional 956,023 shares of common stock for a performance earnout based on PSC's CY 2022 and 2023 financial results. The acquisition is expected to close in the fourth quarter of 2021.

16:17 EST InvenTrust Properties Corp. names David Heimberger CIO - InvenTrust Properties Corp. announced that David Heimberger, InvenTrust's Senior Vice President of Capital Markets, Investor Relations and Transactions has been promoted to the role of Chief Investment Officer, effective immediately. As Chief Investment Officer, Mr. Heimberger will be responsible for developing and executing on InvenTrust's investment strategy, including continuing to lead the Company's transactions team and overseeing all property level acquisitions and dispositions. Mr. Heimberger will also continue to lead the Company's Investor Relations and Capital Markets teams.

16:15 EST Canoo sees FY21 CapEx $60M-$80M, operating expenses $95M-$115M

16:11 EST Gage Growth receives final court approval for acquisition by TerrAscend - Gage Growth Corp. (GAEGF) announced that the Ontario Superior Court of Justice (Commercial List) has issued a final order approving the previously announced plan of arrangement under Section 192 of the Canada Business Corporations Act pursuant to which TerrAscend Corp. (TRSSF) will acquire all of the issued and outstanding securities of Gage. "We are thrilled to announce that the Arrangement has received the necessary approvals from the courts," said Fabian Monaco, CEO of Gage. "As consumer demand for high quality cannabis escalates across the U.S., we look forward to maximizing our cultivation, manufacturing and retail capabilities once we become official members of the TerrAscend team." The Arrangement remains subject to customary closing conditions, including the receipt of certain cannabis regulatory approvals in the State of Michigan.

16:10 EST Kezar Life Sciences reports interim results from MISSION Phase 2 trial - Kezar Life Sciences reported interim results from the Phase 2 portion of its MISSION clinical trial evaluating KZR-616, a first-in-class selective immunoproteasome inhibitor, in patients with active, proliferative lupus nephritis. "The MISSION Phase 2 interim results present a strong signal that KZR-616 is active and could be a meaningful therapy for patients with lupus nephritis, a long term and difficult to treat disease," said Noreen R. Henig, M.D., Kezar's Chief Medical Officer. "Reduction in proteinuria, as quickly as possible, is an important therapeutic goal for patients with lupus nephritis, and we observed meaningful reductions at 6 months as well as encouraging data at 3 months. KZR-616 continues to appear to be immunomodulatory rather than immunosuppressive, which we believe could offer advantages over current treatments available. Based on these interim findings, we look forward to reporting top-line data in the second quarter of 2022." Clinically meaningful renal response was observed at end of treatment. 3 of 5 patients achieved a 50% or greater reduction in UPCR at week 25 compared to baseline, the primary efficacy endpoint of the clinical trial. 4 of the 5 patients who completed treatment at week 25 with KZR-616 demonstrated clinically meaningful reduction in proteinuria to less than 0.8 UPCR: 2 patients showed a CRR and had a reduction of absolute proteinuria values to equal to or less than 0.5 UPCR. 2 patients showed a PRR and had a reduction of absolute proteinuria values to between 0.5 and 0.8 UPCR. Clinically meaningful reductions in UPCR were also observed in 5 of 10 patients at week 13 of KZR-616 and included improvements in key disease biomarkers. KZR-616 was well tolerated over the six-month treatment period. No new safety signals were observed in the Phase 2 portion of the MISSION trial. Adverse events were generally mild-to-moderate. There were no study discontinuations due to drug related adverse events. There was one temporary interruption of study drug due to a Grade 3 serious adverse event, the occurrence of a migraine, and one discontinuation unrelated to the study drug. Top-line data from the Phase 2 MISSION trial in patients with lupus nephritis are expected in the second quarter of 2022.

16:07 EST Intuit names Suzanne Nora Johnson as new board chair - Intuit announced that Suzanne Nora Johnson has been appointed by the Intuit Board of Directors to the role of Board Chair, effective in January 2022, following the Annual Meeting of Shareholders. Brad Smith, who served as CEO of Intuit from 2008 to 2018, Chairman from 2016 to 2018, and Executive Chairman since January 2019, will step down from that position immediately following the Annual Meeting. Smith intends to stand for re-election as a non-executive director of the company at the Annual Meeting.

16:05 EST Charlotte's Web substantially resolved supply chain issues in October - "Temporary supply chain disruptions affected some product availability, dampening revenue growth for the quarter. We substantially resolved these issues in October and are back on our growth trajectory with the holiday buying season in the fourth quarter," explained Wes Booysen, Charlotte's Web Chief Financial Officer. "In parallel, we are streamlining operations and reducing expenses to position the business for positive Adjusted EBITDA in 2022."

16:02 EST Lucid Group surpassed 13,000 reservations in Q3 - Surpassed 13,000 reservations in Q3 for estimated order book of greater than $1.3B. Peter Rawlinson, CEO & CTO of Lucid, said, "We are tremendously excited by our accomplishments in our first quarter as a publicly traded company. We successfully began production of vehicles for customer deliveries, continued investing in capacity expansion of our manufacturing facility in Arizona, and opened new retail and service locations in advance of the Lucid Air launch. We were also pleased to receive independent validation by the EPA of our industry-leading range of over 500 miles for the Lucid Air. Our progress this quarter demonstrates our focus on execution, our cutting-edge technology, and our vision to help with solutions to address the climate challenges we all face. We look forward to ramping up production of our Grand Touring, Touring, and Pure models and expanding our footprint internationally."

16:01 EST Lucid Group confirms win of 2022 MotorTrend Car of the Year

15:11 EST First Guaranty Bancshares announces 10% stock dividend - First Guaranty Bancshares declared a 10% stock dividend to be paid on December 17, with a record date of December 15. "Over the years, continued strong earnings have enabled First Guaranty to declare and issue 10% stock dividends in February 2012, December 2015, December 2017, December 2019, and, presently, December 2021. As the book value has consistently been recovered within 14-17 months, First Guaranty Bancshares, Inc. shareholders have enjoyed enhanced value through both the original dividend income over the period of time plus the overall increase in market value. In addition to the 10% dividends in 2012, 2015, 2017, 2019, and 2021, First Guaranty Bancshares, Inc. has paid 113 consecutive quarterly cash dividends," said Alton Lewis, President and CEO.

14:53 EST Netflix says experiencing issues streaming on Apple devices - Netflix said in a notice posted to its Help Center site: "We are currently experiencing issues streaming on Apple iPad, iPhone, and/or iPod devices; however, other devices may still work. We are working to resolve the problem. We apologize for any inconvenience." Reference Link

14:20 EST Tiger Global boosts stake in Snowflake, exits TAL Education Group - Tiger Global disclosed in an SEC filing its holdings as of September 30, 2021. Tiger's new buys during the third quarter included Warby Parker (WRBY), Robinhood Markets (HOOD), Blend Labs (BLND), VTEX (VTEX), and Matterport (MTTR). Tiger exited one position during the quarter, TAL Education Group (TAL). Tiger increased its stake in Snowflake (SNOW), Sea Ltd (SE), DoorDash (DASH), Datadog (DDOG), and Ozon Holdings (OZON).

13:55 EST 'Halo' TV series streaming in 2022 on Paramount+ - A television series based on Microsoft's (MSFT) "Halo" series of video games will be available to stream in 2022 exclusively on ViacomCBS's (VIAC) Paramount+, according to the series' Twitter account. Reference Link

13:17 EST NuVasive up 7% after Bloomberg says Globus Medical made takeover approach - Shares of NuVasive (NUVA) are up $3.66, or 7%, to $59.82 after Bloomberg's Michelle Davis reported that Globus Medical (GMED) made an approach with an offer for a potential takeover of its smaller rival. The companies have held early talks about a potential combination, sources tells Davis.

13:05 EST Janssen Pharmaceuticals presents clinical data from Phase 2b REEF-1 study - rrowhead Pharmaceuticals (ARWR) collaborator Janssen Pharmaceuticals (JNJ) presented clinical data from REEF-1, a Phase 2b study of different combination regimens, including JNJ-73763989, formerly called ARO-HBV, and/or JNJ-56136379, and a nucleos(t)ide analog for the treatment of chronic hepatitis B virus infection. The data were presented in a late breaking oral presentation at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Disease. JNJ-3989 is an investigational small interfering RNA that targets all hepatitis B virus RNAs, thereby reducing levels of all viral proteins. JNJ-6379 is an investigational capsid assembly modulator that inhibits viral replication by inducing the formation of non-infectious viral particles that are devoid of HBV DNA and RNA. Arrowhead entered into a license and collaboration agreement with Janssen in October 2018 to develop and commercialize JNJ-3989. REEF-1 is a Phase 2b, multicenter, double-blind, active-controlled, randomized study to assess the efficacy and safety over 48 weeks of monthly subcutaneous injections of JNJ-3989 and/or 250mg daily oral JNJ-6379 in combination with daily oral NA in currently not treated or virally suppressed patients with HBeAg positive or negative CHB. Patients were required to have HBsAg levels greater than 100 IU/mL to enter the study. The mean baseline HBsAg level was approximately 3.7 log10 IU/mL across all study arms. The primary endpoint of the study is the proportion of patients meeting NA stopping criteria at the end of treatment. Select data presented include the following: Pharmacodynamic Response in JNJ-3989 200 mg with NA cohort: The greatest reduction in HBsAg was observed in the JNJ-3989 200 mg with NA cohort. A dose dependent response was observed in other cohorts. At week 48, 19.1% of patients met NA stopping criteria. Up to week 72, an additional 10.6% of patients met NA stopping criteria for a total of 29.7%. At week 48, the mean reduction in HBsAg from baseline was 2.6 log10. At week 72, the mean reduction in HBsAg from baseline was 1.9 log10. At week 48, 74.7% of patients achieved HBsAg less than 100 IU/mL. Summary: A dose dependent response was observed. JNJ-3989 200 mg arm at Week 48:. 19.1% of patients met the primary endpoint. The greatest reduction of HBsAg levels from baseline. 74.7% of patients achieving HBsAg less than100 IU/mL. All regimens within this long-term study were generally well tolerated and have a favorable safety profile. Combination studies involving different mechanisms of action are ongoing.

12:58 EST McLaren denies report on sale to Audi - McLaren Group released a statement on recent media reports, saying it is aware of a news media report stating it has been sold to Volkswagen's (VWAGY) Audi (AUDVF). "This is wholly inaccurate and McLaren is seeking to have the story removed," McLaren said. "McLaren's technology strategy has always involved ongoing discussions and collaboration with relevant partners and suppliers, including other carmakers, however, there has been no change in the ownership structure of the McLaren Group." Reference Link

12:56 EST Air Lease signs deal with Airbus covers 111 aircraft - Air Lease (AL) has signed a Letter of Intent covering all Airbus (EADSY) Families, highlighting the power of the company's full product range. The agreement is for 25 A220-300s, 55 A321neos, 20 A321XLRs, four A330neos and includes seven A350Fs. The order which will be finalised in the coming months, makes the Los Angeles based ALC one of Airbus' largest customers and lessor with the biggest A220 order book. Founded in 2010, ALC has ordered a total of 496 Airbus aircraft to date. With this order ALC and Airbus are launching a multi-million dollar ESG fund initiative that will contribute towards investment into sustainable aviation development projects that will in the future be opened to multiple stakeholders from the aircraft leasing and financing community and beyond. "This new order announcement is the culmination of many months of hard work and dedication by both organizations to optimize and fine tune the size and scope of this large aircraft transaction in view of the rapidly growing global airline demand to modernize their jet fleets through the ALC leasing medium," said Steven F Udvar-Hazy, Executive Chairman of Air Lease Corporation. "After lengthy and detailed consultations with several dozen of our strategic airline customers around the world, we are focusing this comprehensive order on the most desirable and in demand aircraft types, covering the A220, A321neo, A330neo and A350 families. ALC is an international Market Leader in each of these categories of the most modern Airbus product lineup. These multi- year additions of new technology aircraft assets to ALC's expanding portfolio will allow us to grow our revenues and profitability while satisfying our airline customer requirements."

12:23 EST Archer Aviation reports receipt of grand jury subpoenas - In a regulatory filing, Archer Aviation stated: "On April 6, 2021, Wisk brought a lawsuit against us in the United States District Court for the Northern District of California alleging misappropriation of trade secrets and patent infringement... Prior to Wisk bringing the lawsuit against us, on March 30, 2021, one of our employees, who is a former employee of Wisk, had a search warrant executed at his home in connection with a federal investigation. We placed this former Wisk employee on paid administrative leave in connection with this government investigation, which we believe is focused on conduct prior to the employee joining the company. We are cooperating with the investigation of the employee. As of November 12, 2021, the investigation is ongoing. In addition, we and three of our employees, who are also former Wisk employees, received grand jury subpoenas from the United States Attorney's Office for the Northern District of California in relation to the same investigation. The grand jury subpoenas seek documents and information about our business, including our hiring practices and intellectual property. We cannot predict the timing or outcome of the litigation or government investigation or range of reasonably possible loss, if any, from either but a negative result could have a material adverse effect on our financial position, liquidity, operations, and cash flows."

12:14 EST Marathon Digital received SEC subpoena on Hardin data center agreements - In a regulatory filing earlier, Marathon Digital stated: "On October 6, 2020, the company entered into a series of agreements with multiple parties to design and build a data center for up to 100-megawatts in Hardin, MT. In conjunction therewith, the company filed a Current Report on Form 8-K on October 13, 2020. The 8-K discloses that, pursuant to a Data Facility Services Agreement, the company issued 6,000,000 shares of restricted common stock, in transactions exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended. During the quarter ended September 30, 2021, the company and certain of its executives received a subpoena to produce documents and communications concerning the Hardin, Montana data center facility described in our Form 8-K dated October 13, 2020. We understand that the SEC may be investigating whether or not there may have been any violations of the federal securities law. We are cooperating with the SEC."

12:09 EST Coinbase opening tech hubs in Brazil, Singapore - In a company blog post, Coinbase EVP of engineering Manish Gupta said, "Coinbase continues to rapidly grow our Engineering team around the world. As a global company, we need deep technical and market-specific expertise across the key regions we serve. Earlier this year, we established our first tech hub in India, and we continue to aggressively hire in the region across product, engineering, design as well as other roles. Today we're announcing that we're opening up tech hubs and actively building out our Engineering teams in two more countries: Brazil and Singapore. Like India, each has an incredible talent pool of engineers, and we look forward to connecting with world-class talent that can help us achieve our mission. We have already hired senior engineering leaders in both Brazil and Singapore who will act as engineering site leads in these countries, and we are now opening up engineering hiring in both these countries...As a remote-first company, our ambition is to be able to hire anywhere in the world where talent resides. Yet, we also recognize the challenges facing distributed teams, and we work hard at maximizing efficiencies across communications, collaboration, and execution. That's why we recently established three distinct regions of work for our Product and Engineering teams - Americas, EMEA and APAC. This regional framework allows us to think about allocating work and creating communities within similar time zones. Our goal is to have team members all work within a single region, meaning one product team may have members in Brazil, the US and Canada. This model provides managers with increased autonomy, and ensures all team members are working in relatively close time zones. Brazil will align to the Americas region, and Singapore to the APAC region. We plan to continue building hubs in various countries across each region, of various sizes, to help us attract top talent from around the world." Reference Link

12:01 EST F45 Training falls -10.1% - F45 Training is down -10.1%, or -$1.31 to $11.66.

12:01 EST Butterfly Network falls -16.8% - Butterfly Network is down -16.8%, or -$1.45 to $7.16.

12:00 EST Vivint Smart Home rises 15.8% - Vivint Smart Home is up 15.8%, or $1.54 to $11.30.

11:55 EST Take-Two's Private Division acquires Roll7, terms not disclosed - Private Division, a publishing label of Take-Two, announced that it has acquired "OlliOlli World" developer Roll7. The studio is currently developing "OlliOlli World," which will be published by Private Division and is set for launch this winter during Take-Two's fiscal fourth quarter ending March 31, 2022. Terms of the deal were not disclosed.

11:37 EST PhaseBio says REVERSE-IT Phase 3 trial achieved primary reversal endpoint - PhaseBio Pharmaceuticals, in conjunction with its financing and co-development partner for the European Union and China, SFJ Pharmaceuticals announced interim results from REVERSE-IT. REVERSE-IT is PhaseBio's ongoing pivotal Phase 3 trial designed to study the reversal of the antiplatelet effects of ticagrelor with lead product candidate bentracimab in patients who present with urgent surgery or an invasive procedure or experiencing uncontrolled major or life-threatening bleeding. The prespecified interim analysis of 150 enrolled patients demonstrated that bentracimab achieved the primary endpoint of the trial by immediately and sustainably reversing the antiplatelet effects of ticagrelor. As measured by the point-of-care VerifyNow PRUTest platelet function assay, a 135% reduction in platelet inhibition was observed within five to ten minutes after initiation of bentracimab infusion and sustained through all timepoints over 24 hours. More than 90% of eligible patients achieved the co-primary endpoint of the trial, defined as good or excellent hemostasis within 24 hours of initiation of bentracimab therapy. Thrombotic events were reported in 5.3% of patients, with none resulting in death or considered by investigators to be related to bentracimab. Bentracimab was generally well tolerated, with only five non-serious adverse events, reported in three patients, considered by investigators to be related to bentracimab. The most common adverse events were related to pain associated with surgical procedures. The results were presented by Deepak L. Bhatt, M.D., M.P.H., Executive Director of Interventional Cardiovascular Programs at Brigham and Women's Hospital and professor at Harvard Medical School, during a Late-Breaking Science Session at the 2021 American Heart Association Scientific Sessions and have been accepted for publication in NEJM Evidence, a new digital journal from the NEJM Group. Cardiovascular disease remains a leading cause of mortality globally. Orally-administered P2Y12 inhibitors, including ticagrelor, continue to be the mainstay of pharmacotherapy in patients diagnosed with acute coronary syndrome, coronary artery disease and other common cardiovascular diseases because of their demonstrated efficacy in preventing thrombotic events such as myocardial infarction and ischemic stroke. However, hospital admissions of patients on P2Y12 inhibitors who require surgery or experience major bleeding events while persistent on their medication remain a significant driver of global healthcare resource utilization. Within the orally-administered P2Y12 inhibitor class, ticagrelor is unique in that it is the only member of the class that can be reversed, creating a potential safety advantage for patients taking ticagrelor should bentracimab be approved.

11:20 EST Bristol-Myers announces results from Phase 2 AXIOMATIC-TKR study - Bristol Myers Squibb (BMY) in collaboration with Janssen Pharmaceuticals (JNJ) announced results from the Phase 2 AXIOMATIC-TKR study, which showed investigational oral milvexian reduced the risk of postoperative venous thromboembolism in a dose dependent manner without increasing the risk of bleeding compared with enoxaparin in patients undergoing total knee replacement surgery. These data were presented at a Late-Breaking Science session at the American Heart Association Scientific Sessions 2021 and simultaneously published in The New England Journal of Medicine. The trial met both of its pre-specified proof-of-principle requirements: the dose response for efficacy with twice-daily milvexian was significant, and the 12% rate of VTE with combined twice-daily doses of milvexian was significantly lower than the prespecified benchmark rate of 30%. At daily doses of at least 100 mg, the rates of VTE with milvexian were significantly lower than with enoxaparin. There were no major bleeds with milvexian and one with enoxaparin. The rates of major plus clinically relevant non-major bleeds with milvexian and enoxaparin were 0.8% and 1.4%, respectively. Across a 16-fold range of doses, milvexian demonstrated a low risk of major plus CRNM bleeding, with no major bleeds and no dose-response on this composite outcome. The TKR study is the first of two studies to read out from the Phase 2 milvexian program. Results from the ongoing Phase 2 study of milvexian for secondary stroke prevention are expected in the first half of 2022. Bristol Myers Squibb and Janssen thank the patients and investigators involved in this clinical trial.

11:02 EST Aura Biosciences Phase 1b/2 results show reduction in tumor growth rate - Aura Biosciences announced the presentation of data evaluating its first VDC, AU-011, in indeterminate lesions and choroidal melanoma, including final safety and efficacy data from the Phase 1b/2 trial using intravitreal administration, as well as updated safety results from the Phase 2 trial using suprachoroidal administration. The results are presented as part of the American Academy of Ophthalmology 2021 Annual Meeting. "The final safety and efficacy data from the Phase 1b/2 trial using intravitreal administration presented today, along with the data from the Phase 2 trial using suprachoroidal administration, provide a high level of confidence for further clinical development in patients with indeterminate lesions or choroidal melanoma," said Carol Shields, MD, Chief of the Ocular Oncology Service at Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University. The Phase 1b/2 trial evaluated the safety and efficacy of AU-011 using IVT administration for the treatment of ILs and CM. A total of 56 patients were enrolled in the Ph1b/2 trial including the single and multiple dose escalation cohorts and received up to two cycles of therapy. As part of an enrichment strategy agreed with FDA, patients with small tumors with active growth were enrolled in the Phase 2 part of the study. This group of patients received the therapeutic regimen and were evaluated for the tumor growth rate, tumor control, and visual acuity preservation as the efficacy endpoints. These endpoints have been agreed with FDA and are planned to be used in the pivotal program. The results at 12 months showed a statistically significant reduction in the tumor growth rate compared to each patient's documented growth rate at study entry, and a 64% tumor control rate. In addition, the visual acuity preservation rate was 71%, which is unprecedented compared to the current standard of care with radiotherapy. Overall, AU-011 demonstrated a favorable safety and tolerability profile. The majority of adverse events, which included intraocular inflammation and increased intraocular pressure, were transient and resolved without clinical sequelae. A large number of patients had tumors close to the fovea and optic disk and only two patients with juxta-foveal tumors had a treatment related serious adverse event of vision loss. No other treatment related SAEs were observed in the trial. These safety and efficacy results indicate that AU-011 may offer a targeted vision preserving therapy for the first line treatment of CM.

11:02 EST Medtronic reports 510(k) clearance for PillCam Small Bowel 3 @HOME endoscopy - Medtronic announced that the U.S. Food and Drug Administration has granted 510(k) clearance for its PillCam Small Bowel 3 system for remote endoscopy procedures. "The PillCam SB3 @HOME program combines Medtronic's PillCam technology with Amazon logistics, a combination intended to ensure both timely and accurate results for patients from the comfort of their homes," the company said. "PillCam Small Bowel 3 is only cleared for remote use in the U.S. It is not approved for this use in other geographies," Medtronic noted.

10:20 EST Accenture acquires T.A. Cook consultancy, terms not disclosed - Accenture announced it has acquired T.A. Cook, a consultancy headquartered in Berlin, Germany specializing in asset performance management and capital projects for clients in capital-intensive industries and infrastructure. "The acquisition will strengthen Accenture's capabilities for improving asset performance, increasing safety, and reducing environmental impact and cost in the chemicals, life sciences, metals and mining, and oil and gas industries," the company said. Financial terms were not disclosed.

10:00 EST Philips falls -11.2% - Philips is down -11.2%, or -$5.35 to $42.27.

10:00 EST Vector Group rises 12.1% - Vector Group is up 12.1%, or $1.84 to $17.06.

10:00 EST Casper Sleep rises 87.3% - Casper Sleep is up 87.3%, or $3.10 to $6.65.

09:50 EST Icahn confirms 10 director nominees for Southwest Gas board - Icahn Partners LP, a Delaware limited partnership, which is an affiliate of Icahn Enterprises L.P. ( IEP), announced that it has nominated the following ten individuals: Ms. Nora Mead Brownell, Ms. Marcie L. Edwards, Mr. Andrew W. Evans, Mr. H. Russell Frisby, Jr., Mr. Walter M. Higgins III, Ms. Rina Joshi, Mr. Henry P. Linginfelter, Mr. Jesse A. Lynn, Ms. Ruby Sharma, and Mr. Andrew J. Teno to seek election to the board of directors of Southwest Gas Holdings, Inc. (SWX) at Southwest Gas' 2022 Annual Meeting of Stockholders. Icahn Partners submitted its notification of nomination of the Icahn Slate to Southwest Gas earlier today. Carl C. Icahn stated: "We are proud to present our blue-ribbon slate of directors, 8 of whom are entirely independent of IEP in all regards. They are immensely qualified in terms of utility and regulatory experience and reflect a diverse mix of operational, financial, legal, regulatory and governance experts. We believe our slate of directors can greatly enhance stockholder and ratepayer value." Reference Link

09:47 EST Edenor falls -9.2% - Edenor is down -9.2%, or -55c to $5.45.

09:47 EST Butterfly Network falls -12.8% - Butterfly Network is down -12.8%, or -$1.10 to $7.50.

09:47 EST Vivint Smart Home rises 9.6% - Vivint Smart Home is up 9.6%, or 94c to $10.70.

09:45 EST Applied DNA Sciences subsidiary LineaRx receives repeat orders for LinearDNA - Applied DNA Sciences and its majority-owned subsidiary LineaRx announced the receipt of repeat orders from diagnostic customers and a first Contract Research Organization order from a new biotherapeutic customer, a federally funded research and development laboratory focused on cancer research. PCR-produced LinearDNA serves as a pure, fast, and flexible alternative to plasmid DNA in the manufacture of cell and gene therapies and nucleic acid vaccines. CRO orders typically provide a means to evaluate LinearDNA within a customer's preclinical development program. :ineaRx has recorded an uptick in CRO orders for LinearDNA in recent quarters. Although a limited number of CGTs are currently on the market, FDA officials predicted in 2019 that the agency will receive more than 200 investigational new drug applications per year for cell and gene therapies and that by 2025, it expects to have accelerated to 10 to 20 cell and gene therapy approvals per year1. As a result of the COVID-19 pandemic, nucleic acid therapies have also moved to the forefront of biotherapeutic science with the successful deployment of mRNA vaccines against the virus. Most evaluations of LinearDNA currently center on its use in the development of preclinical CAR T therapies, a use case highlighted in a recently published study that utilized LinearDNA in a non-viral manufacture of CD19-specific CAR T cells2. CRO customers are also evaluating LinearDNA for use in mRNA template manufacture, recombinant adeno-associated virus manufacture, and in vivo expression vectors.

09:43 EST Humacyte presents 12-month data from HAVs - Humacyte announced that data from a Phase 2 clinical trial of patients receiving the human acellular vessel produced using its cutting-edge, large-scale manufacturing systems, known as "LUNA200", for vascular access in hemodialysis, demonstrated 12-month efficacy that is similar to trials of HAVs produced in the development-scale systems previously used in manufacturing the HAV. The Phase 2, prospective, multicenter, open-label, single-arm study evaluated the safety, efficacy and immunogenicity of HAVs manufactured with the commercial-scale LUNA200 platform in 30 end-stage renal disease patients undergoing hemodialysis. One year after implantation, 83% of subjects still showed secondary, or functional, patency. Secondary patency rates of the HAVs produced using the prior, development-scale systems ranged from 82% to 89%. No instances of HAV rupture, aneurysm formation or acute mechanical failure were observed in the study. In addition, the HAV appears to resist infection as compared to synthetic conduits. Each modular, automated LUNA200 system, with enhanced process controls, can grow 200 HAVs at a time. Humacyte's LUNA200 systems are housed in its 83,000-square-foot state-of-the-art bioprocessing facility in Durham, N.C., which has ample space to house enough systems to produce an annual capacity of approximately 40,000 HAVs per year. The Durham facility is fully operational, and in 2021 the FDA authorized the use of HAVs produced in the LUNA200 system to supply the Company's ongoing clinical trials in the United States. The facility also achieved compliance with EU good manufacturing practices and Qualified Person Certification to allow product to be supplied to ongoing studies in Europe and Israel. The 12-month data were presented at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society. The secondary objective of this study is to evaluate the long-term safety and efficacy of the HAV manufactured with the LUNA system for up to 36 months after implantation, and the study is ongoing.

09:40 EST Tyson Foods: Demand 'incredibly strong' across portfolio

09:38 EST Stereotaxis says BJC HealthCare offers Genesis RMN system - Stereotaxis announces that BJC HealthCare has become the first health care system in the midwest to offer the Genesis RMN system, advancing electrophysiology patient care and expanding access to advanced robotic technology for the treatment of cardiac arrhythmias in the greater St. Louis region.

09:35 EST Compass Diversified announces proposed private offering of $300M - Compass Diversified announced that the Company intends, subject to market and other conditions, to commence an offering of $300 million of senior unsecured notes due 2032 in a private offering. The Company intends to use the net proceeds of the Notes offering to repay a portion of the outstanding balance under the Company's existing revolving credit facility.

09:33 EST Mid Penn Bancorp receives regulatory approvals for Riverview Financial merger - Mid Penn Bancorp (MPB) and Riverview Financial Corporation (RIVE) announced that they have received all required approvals from the applicable bank regulatory agencies to complete the proposed merger of Riverview with and into Mid Penn. Pending receipt of approval from shareholders of Mid Penn and Riverview, and certain other customary closing conditions, the parties intend to close the transaction in the fourth quarter of 2021. Following completion of the merger, Riverview Bank will be merged with and into Mid Penn Bank. "We are pleased to have received regulatory approval of our merger that supports our growth objectives, complements our franchise, and propels long-term shareholder value," said Mid Penn President and CEO Rory G. Ritrievi. "Mid Penn and Riverview continue to work collectively towards a fourth-quarter closing of this transaction and are meeting timelines and milestones as expected." The merger will extend Mid Penn's footprint into new markets, including the Lehigh Valley and State College region, and will expand its presence in Western Pennsylvania. Mid Penn, on a pro forma basis following completion of the merger, is projected to have $4.7B in assets.

09:31 EST Sage Group kicks off Sage Sessions X3 - Sage kicks off its annual Sage Sessions X3 conference in Orlando. The hybrid event for Sage X3 customers and partners, held Nov. 15-17, offers attendees both in-person and virtual experience options. With keynotes and breakout sessions delivered by Sage leaders, customers, and partners, the event is designed to provide the Sage X3 community with the tools to help them grow their business with Sage.

09:30 EST Armstrong World releases inaugural sustainability report - Armstrong World released its inaugural sustainability report. Report highlights include: a comprehensive set of science-based targets for 2030, including, among others, a 30% absolute reduction in Scope 1 and 2 greenhouse gas emissions, a shift to 100% renewably sourced electricity, and a 50% absolute reduction in waste from operations; commitment to transparency and accountability through globally recognized reporting frameworks such as the Global Reporting Initiative, the Sustainability Accounting Standards Board and the Task Force for Climate-Related Disclosure; establishment of an enterprise Sustainability Council and clear governance structure to support execution and oversight of sustainability strategy and initiatives: and ontinuation of efforts to promote and maintain an inclusive and diverse workforce under Selena Coachman, VP of Talent Sustainability, Diversity and Inclusion.

09:28 EST Verizon appoints Samantha Hammock as Chief Human Resources Officer - Verizon appointed Samantha Hammock to Executive VP and Chief Human Resources Officer of Verizon, effective December 1. Before joining Verizon as the Senior VP of Global Talent, Hammock spent 14 years at American Express, most recently as the Head of Talent and Learning.

09:28 EST Tyson Foods: Board last week approved 6% increase to dividend

09:26 EST AnaptysBio: Rosnilimab showed favorable safety in Phase 1 trial - AnaptysBio announced top-line data from a randomized placebo-controlled healthy volunteer single and multiple ascending dose Phase 1 trial of rosnilimab, its investigational wholly-owned anti-PD-1 agonist therapeutic antibody, previously known as ANB030. Top-line data demonstrated favorable safety, pharmacokinetics and pharmacodynamic results that support advancement of rosnilimab into subsequent patient trials. A total of 144 subjects were enrolled in the randomized, double-blind, placebo-controlled healthy volunteer Phase 1 trial, where single ascending dose cohorts were administered single subcutaneous or intravenous doses of rosnilimab ranging between 0.02mg to 600mg or placebo, while multiple ascending dose cohorts received four weekly subcutaneous doses of rosnilimab ranging between 60mg and 400mg or placebo. Dose escalation was conducted subsequent to data safety monitoring board review of safety and tolerability parameters following each single and multiple ascending dose level. Rosnilimab was generally well-tolerated and no dose limiting toxicities were observed. The most frequent adverse event reported among SAD cohorts was increased circulating C-reactive protein levels of mild severity in nine rosnilimab-dosed subjects occurring sporadically in a dose-independent manner and a severe occurrence in one placebo-dosed subject. MAD cohorts reported headache as the most frequent adverse event with mild occurrences in three rosnilimab-dosed subjects and none in placebo subjects. Mild injection site reactions were observed in two subjects administered with multiple subcutaneous rosnilimab doses. Two serious adverse events were reported in single dose cohorts, including obstructive pancreatitis in a placebo-dosed subject and COVID-19 infection in a rosnilimab-dosed subject leading to discontinuation which was deemed unrelated to treatment. No serious adverse events were reported in subjects receiving multiple doses of rosnilimab or placebo.

09:26 EST ElectraMeccanica to showcase lineup of SOLO EVs at LA Auto Show - ElectraMeccanica Vehicles announced the Company will showcase its vehicles at the Los Angeles Auto Showtaking place November 17-28, 2021 at the Los Angeles Convention Center. The ElectraMeccanica booth will be located near the West Hall Main Entrance. The Company will display multiple versions of its flagship, single-seat SOLO EV. In addition, ElectraMeccanica will offer free, scheduled test drives to consumers and the media to experience the SOLO EV on a surface street on-site, at the event.

09:25 EST Washington Trust rebrands wealth management division - The Washington Trust Company announced it is rebranding its wealth management offices across Rhode Island, Massachusetts, and Connecticut under one unified name: "Washington Trust Wealth Management." The name, Washington Trust Wealth Management, is already in use by the company's RI-based wealth management group, and will now encompass Wellesley, MA-based Weston Financial Group and New Haven, CT-based Halsey Associates, which were acquired by Washington Trust in 2005 and 2015, respectively, but until now had retained the use of their own names. "Through both organic growth and strategic acquisitions, Washington Trust has built one of New England's premier boutique advisory groups, with more than $7 billion in assets under administration," stated Edward Handy III, Chairman and Chief Executive Officer. "The rebranding effort is a natural evolution of the growth and maturation of our wealth management division and name reflects the strength and stability of our 220+ year old parent company."

09:23 EST Usio promotes Greg Carter and hires Steve Peterson - Usio promoted Greg Carter to Executive VP of Payment Acceptance and hired payments industry veteran Steve Peterson. Peterson was most recently engaged with PaySign as their SVP of Business Development and senior business development positions with FIS, GreenDot, and NetSpend.

09:22 EST Quantum FinTech announces co-placement agents for PIPE - Quantum FinTech Acquisition Corporation announced that its advisors in connection with the PIPE to close at or about the time of its proposed initial business combination include Piper Sandler & Co., as financial advisor to Quantum FinTech, Chardan as M&A advisor to Quantum FinTech, Piper Sandler as lead placement agent, and Chardan and Marco Polo Securities Inc. as co-placement agents.

09:19 EST Clene completes patient enrollment in Healey ALS Platform trial - Clene completed enrollment in the HEALEY ALS Platform Trial, led by the Sean Healey & AMG Center for ALS at Massachusetts General Hospital. Clene's lead drug candidate, CNM-Au8, which has received FDA Orphan Drug designation for the treatment of amyotrophic lateral sclerosis, is one of several drugs being evaluated in this innovative platform trial. The HEALEY ALS Platform Trial is a multi-center clinical program evaluating the safety and efficacy of multiple investigational products in ALS patients. Clene's CNM-Au8, a catalytically active gold nanotherapeutic, was selected by the Healey Center Therapy Selection Committee to be one of the first entrants into the trial. Clinical data from an additional 80 placebo-treated participants are shared within the platform trial from two other regimens for an overall 1:1 allocation of active:placebo.

09:18 EST American International Holdings launches Ambassador Program for EPIQ MD - American International Holdings announced that its subsidiary EPIQ MD has launched its much-anticipated Ambassador Program. This groundbreaking initiative will combine community, entrepreneurship, and technology to bring healthcare solutions to the near 80 million uninsured and underinsured, hardworking U.S. residents who have been left behind by ever-increasing insurance and medical costs. With the introduction of Epiq MD's Ambassador Program, AMIH believes they have set up the perfect mix of direct sales and organic community involvement, both of which have been largely missing components in the traditional healthcare industry. Epiq MD's Ambassador Program aims to bind entrepreneurship with stewardship in an innovative manner creating leaders in communities all across the nation. Accordingly, the Company is confident this will grant them a significant competitive advantage.

09:17 EST Navient supports New Boys & Girls Clubs of America curriculum - Navient and Boys & Girls Clubs of America announced the launch of a new digital program to help young people and their families learn about financial aid and how to pay for college. This online program expands upon Diplomas to Degrees, Boys & Girls Clubs of America's college readiness program, to guide high schoolers through their postsecondary education and career planning journeys.

09:16 EST Fluent to appoint Sugandha Khandelwal as CFO - Fluent appointed Sugandha Khandelwal as CFO effective December 6. CFO Alex Mandel since 2018 will continue in the role until the effective date of Khandelwal's appointment and will assist with the transition through December 31. Prior to joining Fluent, she served as Chief Financial Officer of the Consumables and Health & Wellness businesses at Sam's Club, a division of Walmart. Prior to this role, Sugandha was Head of Financial Planning, Strategy and Business Development at Walmart U.S. Merchandising organization.

09:14 EST SunLink Health Systems provides COVID-19 update - The company said, "...Going forward, the Company is unable to determine the extent to which the COVID-19 pandemic will continue to affect its assets and operations. Our ability to make estimates of the effect of the COVID-19 pandemic on revenues, expenses or changes in accounting judgments that have had or are reasonably likely to have a material effect on our financial statements is currently limited. The nature and extent of the effect of the COVID-19 pandemic on our balance sheet and results of operations will depend on the severity and length of the pandemic; government actions to mitigate the pandemic's effect; regulatory changes in response to the pandemic, especially those that affect our hospital, extended care, rehabilitation center and nursing home and clinics, and our pharmacy operations; existing and potential government assistance that may be provided; and the requirements of PRF receipts, including our ability to retain such PRF received."

09:13 EST 3D Systems advances production applications with additive solutions - 3D Systems announced a host of innovations designed to enhance customer success and catalyze industries. The company is introducing high-throughput 3D printing technologies, a new partnership to provide industry-leading post-processing, improved additive manufacturing software, and a new production-grade photopolymer. The company introduced its next-generation selective laser sintering workflow that combines 3D Systems' new SLS 380, 3D Sprint, DuraForm materials, and AMT's PostPro. The company is announcing the DMP Flex 350 Dual and DMP Factory 350 Dual that include two lasers that help reduce build time by up to 50% and lower cost.

09:13 EST Collegium Pharmaceutical authorizes $25M accelerated share repurchase program - Collegium Pharmaceutical has entered into an Accelerated Share Repurchase agreement with Jefferies to repurchase $25M of the company's common stock. Collegium will execute the ASR as part of the $100M share repurchase program authorized by its Board of Directors in August. Upon completion of this ASR, Collegium will have $52.2M remaining under the authorization. Collegium will pay $25 million to Jefferies LLC and will receive approximately 1,026,694 shares, based on the $19.48 closing stock price of Collegium's common stock on November 12, 2021, representing approximately 80% of the total shares the company expects to repurchase under the ASR agreement. The final number is expected to be completed in 1Q22. As of September 30, Collegium had approximately 34.8M shares outstanding.

09:11 EST SmileDirectClub announces next generation treatment planning system SmileOS - SmileDirectClub has announced SmileOS, the company's new treatment planning software that enables its affiliated network of state-licensed doctors to treat more patients, more accurately predict tooth movements, and better visualize their patients' treatment. "Our proprietary, custom-built SmileOS treatment planning software exceeds the capabilities of the off-the-shelf solutions used by many of our competitors and helps us deliver a superior customer experience," said Dr. Jeffrey Sulitzer, Chief Clinical Officer, SmileDirectClub. "SmileDirectClub has a legacy of unprecedented innovation and vertical integration, creating in-house expertise in retail, manufacturing, and distribution operations, as well as treatment planning software with SmileOS. This translates to an unmatched customer experience and even better treatment outcomes."

09:11 EST FactSet appoints Kendra Brown Head of Investor Relations - FactSet has appointed Kendra Brown Senior Vice President, Investor Relations. She will replace Rima Hyder, Senior VP, Investor and Media Relations. Hyder has resigned from FactSet to pursue other opportunities, effective December 10. Kendra Brown is currently Senior VP and Chief of Staff to the CEO at FactSet. Prior to this role, she was Director of Product Development within FactSet's Research & Advisory workflow solutions business. Brown joined FactSet in 1999.

09:10 EST GSE Systems wins contract to support nuclear-powered energy data center campus - GSE Systems announces a new contract with Talen Energy to support development of its subsidiary, Cumulus Data's, flagship Susquehanna Hyperscale Data Center Campus. GSE DP Engineering, a longtime Talen Energy Engineer of Choice service provider, is part of a multi-faceted, multi-company team supporting the project initiative. Talen Energy is developing a cryptocurrency mining facility and data center on the campus, which is adjacent to Susquehanna Steam Electric Station in Salem Township, Luzerne County, PA and will be powered by the nuclear power plant. "We are pleased to continue our support of Talen Energy and Cumulus as their operations expand into the carbon free powered data center space," said Kyle Loudermilk, President and Chief Executive Officer of GSE Solutions. "As the adoption of technology advances, and consumes ever more energy, there is increasing demand for zero carbon energy for data centers that support applications like cloud computing, data storage and cryptocurrency processing. Nuclear energy provides highly reliable, 24/7 carbon free power and is a natural fit for these essential data centers. GSE is proud to help with the design of infrastructure to bring nuclear as the carbon free energy source to the new SHC. It's exciting to be part of such an innovative endeavor, and we look forward to further opportunities to advance carbon free power applications such as this." The project is expected to come online in Q2 2022.

09:09 EST Coherus Biosciences, Junshi announce orphan drug designation for toripalimab - Coherus BioSciences and Shanghai Junshi Biosciences announced that the United States Food and Drug Administration has granted Orphan Drug Designation for toripalimab for the treatment of esophageal cancer. Orphan drug designation is granted to drugs and biologics intended to treat rare diseases with a patient population less than 200,000 in the U.S. The designation provides incentives to advance development and commercialization of rare disease drugs. In September, Coherus and Junshi Biosciences announced results of the Phase 3 clinical trial, JUPITER-06, a randomized, double blind, placebo-controlled study evaluating toripalimab in combination with chemotherapy as a first-line therapy for patients with advanced or metastatic ESCC. The study met the co-primary endpoints with statistically significant and clinically meaningful improvements in progression free survival and overall survival for patients treated with the toripalimab and chemotherapy combination, compared to chemotherapy alone. In 2022, Coherus and Junshi Biosciences are planning to submit a biologics license application supplement to the FDA for toripalimab in combination with platinum-based chemotherapy for the first-line treatment of advanced or metastatic ESCC. A BLA for toripalimab for advanced recurrent or metastatic nasopharyngeal carcinoma is currently under priority review by the FDA with a target action date of April 2022.

09:08 EST Meredith announce pending acquisitions by Gray, Dotdash get regulatory approval - Meredith (MDP) announced that its pending acquisitions by Gray Television (GTN) Inc. and IAC's (IAC) Dotdash Media received key regulatory approvals. First, the Federal Communications Commission has approved Gray's acquisition of Meredith, and Meredith will now seek the transaction's approval at a November 30, 2021, special shareholder meeting. Immediately prior to the Gray acquisition, Meredith will spin its digital, magazine, MNI, PEOPLE TV, and corporate operations out to shareholders as a new company, Meredith, that Dotdash has agreed to acquire. Additionally, Meredith announced the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976 for Meredith Holdings' acquisition by Dotdash expired on November 12, 2021. Meredith continues to expect both transactions to close on December 1, 2021, subject to shareholder approval of Gray's acquisition, and subject to the satisfaction of the other terms and conditions of the merger with Gray, as well as the spin-off of Meredith Holdings and its merger with Dotdash.

09:07 EST NXP Semiconductors announces launch of senior unsecured notes offering - NXP Semiconductors announced that its subsidiaries NXP B.V., NXP Funding LLC and NXP USA, intend to commence a private offering of senior unsecured notes pursuant to Rule 144A and Regulation S under the U.S. Securities Act of 1933, as amended. The Notes will be fully and unconditionally guaranteed on a senior basis by NXP Semiconductors N.V. and will be structurally subordinated to the liabilities, including trade payables, of NXP's other subsidiaries. In addition, the Notes will be effectively junior to all future secured debt of the Issuers and NXP Semiconductors N.V., to the extent of the value of the assets securing such debt. NXP intends to use a portion of the net proceeds from the offering of the Notes to redeem the $1,000 million aggregate principal amount of outstanding dollar-denominated 3.875% senior unsecured notes due 2022 in accordance with the terms of the indenture governing the 3.875% 2022 Notes, including all premiums, accrued interest and costs and expenses related to the 3.875% 2022 Notes Redemption. NXP intends to use the remaining net proceeds for general corporate purposes, which may include capital expenditures or equity buyback transactions.

09:04 EST Celularity presents preclinical data on allogeneic genetically-modified NK cells - Celularity reported its findings in a poster presentation at the Society for Immunotherapy of Cancer Annual Meeting held in Washington, D.C., November 10-14, 2021. Poster 159: "Developing placental CD34+-derived natural killer cells with high affinity cleavage resistant CD16 and Cetuximab for enhanced therapy of EGFR+ non-small cell lung and head and neck cancers" Highlights: CYNK-101 is a cryopreserved off the shelf allogeneic NK cell product, overexpressing a high IgG binding affinity, proteinase cleavage resistant, CD16 variant. The results demonstrate the synergistic effect of combining CYNK-101 with Cetuximab to drive antibody dependent cellular cytotoxicity activity against EGFR+ tumors. Further development of the combinational therapy against EGFR+ non-small cell lung cancer and head and neck squamous cell carcinomas is warranted.

09:02 EST Atlas Air partners with Cainiao to operate Asia-Latin America flights - Atlas Air Worldwide Holdings announced its Atlas Air, Inc. subsidiary has expanded its partnership with Cainiao Network, the logistics arm of Alibaba Group, to enhance overall shipping efficiency in response to the growth of cross-border trade between China and Latin America. With the launch of daily flights, Cainiao's weekly cargo volume from China to Latin America has increased 144% compared to last October when there were only three chartered flights per week. Under the expanded agreement, Atlas has added an additional B747-400F to fly between Hong Kong, China and Santiago, Chile. This brings the total dedicated fleet that Atlas operates for Cainiao to five aircraft. This expanded fleet builds upon the successful collaboration between Atlas and Cainiao, which was launched in October 2020, with Atlas operating three weekly charter flights dedicated to Cainiao, linking Hong Kong with Brazil and Chile. The current upgraded Atlas-Cainiao partnership has enhanced overall warehouse distribution and air freight efficiency by over 40%.

09:02 EST Bionano Genomics to present at Association for Molecular Pathology meeting - Bionano Genomics announced the lineup of content scheduled to be presented at the annual meeting of the Association for Molecular Pathology. The content is expected to include an oral platform presentation, six poster presentations, a corporate workshop and an innovation spotlight. The presentations span a range of applications, including prenatal analysis, genetic disease, hematological malignancies, solid tumor and advances in the OGM technique for detecting more clinically relevant variants. The content for the spotlight will cover Bionano's efforts in building a cancer knowledgebase for interpreting variants faster, the power of combining OGM and NGS data to reveal significantly more clinically relevant variants than with NGS alone and an illustration of an application of OGM as an alternative to karyotyping and FISH for revealing complex, clinically relevant structural variants in an aggressive leukemia/lymphoma subject.

09:01 EST Chembio Diagnostics ennounces extension of delivery schedule - Chembio Diagnostics announced that the delivery schedule for shipments of DPP SARS-COV-2 Antigen Tests under its July 2021 purchase order from Bio Manguinhos has been extended into March 2021. As the result of a portion of the shipments now being deliverable after year end, Chembio believes it now has the opportunity to fulfill all of the $28.3 million order. Chembio's delivery of tests covered by the purchase order, however, continues to be negatively affected by limitations of Chembio's supply chain, staffing, and liquidity, and other matters outside Chembio's control. The DPP SARS-CoV-2 Antigen test is designed to detect the SARS-CoV-2 antigen, which indicates an active COVID-19 infection, in only 20 minutes using a minimally invasive nasal swab.

09:00 EST Oncternal Therapeutics presents interim Phase 1/2 trial data for ONCT-216 - Oncternal Therapeutics announced updated interim clinical data from the Phase 2 expansion cohort of its ongoing Phase 1/2 clinical trial evaluating ONCT-216, an investigational, potentially first-in-class, targeted small-molecule inhibitor of the E26 transformation-specific family of oncoproteins, in patients with relapsed or refractory Ewing sarcoma. The data update was delivered in an oral presentation at the Connective Tissue Oncology Society 2021 Virtual Annual Meeting. ONCT-216 remains generally well tolerated. As of the October 1, 2021 data cutoff date, the most common drug-related adverse events included myelosuppression, fatigue, alopecia, nausea, pyrexia, and decreased appetite. The myelosuppression was primarily neutropenia, which was transient and readily managed. No unexpected off-target toxicities have been observed.

08:59 EST MultiPlan issues letter to stockholders regarding short seller allegations - MultiPlan released a letter to its stockholders on its website. The letter said, "As you know, MultiPlan's fundamentals have never been stronger. Since going public, we have reported five consecutive quarters of strong earnings. We continue to integrate our recent strategic acquisitions, and we recently refinanced our debt to significantly extend maturities. In October, we raised both the midpoint of our full-year 2021 revenue guidance and raised our full-year 2021 EBITDA guidance. Unfortunately, our strong fundamental performance has been overshadowed by the unsubstantiated allegations by short sellers - motivated by their own economic self-interest - that our largest customer, UnitedHealthcare (UHC), is planning to terminate its relationship with MultiPlan. Recent sworn testimony makes clear UHC's position with respect to its relationship with MultiPlan, and further supports our previous comments that these short-seller assertions are false. Along with many others, we have been closely following the ongoing litigation between UHC and an emergency physician staffing business. Last week, a document that called MultiPlan's and UHC's relationship into question surfaced in that trial and became a subject of interest in the securities markets. Later in the week, however, a recently retired UHC senior executive testified under oath that, as recently as August 2021, when he left UHC, UHC had no plan in place to terminate its contract with MultiPlan and had not created a product or service to replace MultiPlan. This senior executive, who oversaw the MultiPlan relationship, also attested to the strength and the interconnectedness of the commercial relationship between UHC and MultiPlan. The false UHC "termination" narrative has been deployed tactically by opportunistic short sellers seeking to profit at the expense of MultiPlan's shareholders and bondholders. Last week's trial testimony by this executive directly contradicts this narrative. MultiPlan has been closely following the trial testimony and wishes to share the following key takeaways directly from what we heard from the broadcast of the trial... The bottom line is that MultiPlan's relationship with UHC remains strong and recent sworn testimony contradicts the false suggestion that UHC intends to terminate that relationship. MultiPlan has built a business over decades by working with payors, providers and patients to expand care while reducing costs. In 2020, we processed approximately $105B in billed charges and identified approximately $19B in potential savings opportunities for payors, healthplans and plan members. UHC is one of our many partners with whom we work closely to deliver significant savings to consumers and their employers. We plan to continue to grow our platform to benefit and drive value for our customers, employees and stockholders, and we remain fully committed to acting in the best interests of our stockholders and other stakeholders in the years to come."

08:57 EST James River Group appoints Mike Hoffman as group chief underwriting officer - James River Group Holdings announced that Mike Hoffmann has joined the Company as Group Chief Underwriting Officer. In a newly created role, Mr. Hoffmann will lead a team with responsibility for underwriting, enterprise risk and ceded reinsurance strategy across the Group. Mike joins James River most recently from Everest where he was Head of Risk and Ceded Re. Prior to then, he spent 15 years with Allied World Assurance, where he most recently served as Global Insurance Chief Underwriting Officer. Prior to Allied World, Mike spent 14 years with Chubb in a variety of roles in the U.S. and Bermuda. At James River, he will report into Chief Executive Officer Frank D'Orazio.

08:55 EST Novavax announces submission of BLA in South Korea for NVX-CoV2373 - Novavax and SK bioscience announced the submission of a Biologics License Application, BLA, for Novavax' COVID-19 vaccine to South Korea's Ministry of Food and Drug Safety, MFDS. NVX-CoV2373, Novavax' recombinant nanoparticle COVID-19 vaccine with Matrix-M adjuvant, is the first protein-based COVID-19 vaccine to be submitted for BLA in Korea. "Today's submission reflects the first BLA submission for full approval of our COVID-19 vaccine anywhere in the world, with more anticipated to follow," said Stanley Erck, President and Chief Executive Officer, Novavax. "Our partnership with SK bioscience reinforces our shared commitment to global equitable access as we work together to deliver our COVID-19 vaccine, built on a proven, well-understood vaccine platform." In collaboration with Novavax, SK bioscience initiated the rolling submission process for NVX-CoV2373 to the MFDS in April of this year. The completion of a BLA submission to the MFDS marks the final review stage for authorization of NVX-CoV2373 in Korea. Novavax and SK bioscience have an existing manufacturing and licensing collaboration that is intended to provide broad and equitable access to NVX-CoV2373 both in Korea and globally through the COVAX Facility. SK bioscience finalized an advance purchase agreement with the Korean government to supply 40 million doses of NVX-CoV2373 to South Korea earlier this year.

08:54 EST NMI Holdings COO Patrick Mathis to retire - NMI Holdings announced that Norm Fitzgerald, currently the company's Senior Vice President and Chief Sales Officer, has been appointed Executive Vice President and Chief Sales Officer, and Mohammad Yousaf, currently the company's Senior Vice President and Chief Business Transformation Officer, has been appointed Executive Vice President, Operations and IT. Both promotions will take effect on January 1, 2022. In addition to the executive appointments, National MI announced the retirement of Patrick Mathis, currently the company's Executive Vice President and Chief Operating Officer, effective April 1, 2022. Mr. Mathis joined National MI as Chief Risk Officer in 2012 and assumed responsibility as Chief Operating Officer in 2018.

08:52 EST SPX Corporation to purchase Cincinnati Fan from Dominus Capital - Dominus Capital announced that it has entered into a definitive agreement to sell Cincinnati Fan & Ventilator to SPX Corporation. "Dominus has been an excellent partner for Cincinnati Fan," said Paul Burton, President and CEO of Cincinnati Fan. "Dominus supported our growth with strong industry expertise and capital. We completed and integrated two strategic acquisitions and successfully launched new products to deliver more solutions to our customers. Dominus allowed us to maintain our core Cincinnati Fan DNA, while providing the resources to accelerate our growth story." The transaction is expected to close by year end 2021 and is subject to regulatory approval and customary closing conditions. Other terms of the transaction are not being disclosed at this time.

08:51 EST Badger Infrastructure announces change to quarterly dividend - Badger Infrastructure Solutions is pleased to announce its November 2021 cash dividend and announce a change to a quarterly cash dividend in 2022. Badger announced that the directors of Badger declared a cash dividend for the month of November 2021 of $0.0525 per share, which equates to $0.63 per share on an annualized basis. Payment will be made on or about December 15, 2021, to shareholders of record on November 30, 2021. Badger expects that the dividend will be an "eligible dividend" for Canadian income tax purposes and thus qualify for the enhanced gross-up and tax credit regime for certain shareholders. As previously announced on November 4, 2021, Badger's board of directors approved a change in the frequency of the Company's cash dividend payment from monthly to quarterly effective with its March 2022 dividend. The March 2022 quarterly cash dividend will be payable on April 15, 2022 to all shareholders of record at the close of business on March 31, 2022.

08:50 EST Immutep presents new data for LAG-3 therapy at SITC Annual Meeting - Immutep announced new data published in poster presentations at the Society for Immunotherapy of Cancer - SITC - Annual Meeting 2021 from 10-14 November the US. The new data relates to the company's Phase IIb AIPAC trial and Part C of its Phase II TACTI-002 study. In addition, a poster presentation of the trial design of the company's new randomised Phase IIb study in 1st line HNSCC was also presented at SITC. All three poster presentations relate to Immutep's lead candidate efti. CEO Marc Voigt commented: "The combination of the OS data in the prespecified subgroups, immune monitoring data and Quality of Life data, which were all statistically significant, give us confidence as we move forward with the development of efti in various late-stage settings...we have seen across our various studies that efti, with its unique mechanism of action, has the potential to benefit many cancer patients, including those with more limited treatment options." Overall Survival data from the abstract published on 9 November included statistically significant benefit in 3 patient subgroups representing a majority of patients, a statistically significant Quality of Life preservation in first 6 months in the efti group in total population; the statistically significant increase in peripheral CD8 T cells in patients in the efti group of the total population and the statistically significant correlation of this increase with improved OS; the TACTI-002 poster presentation showed an Overall Response Rate with 29.7% ) of 2nd line HNSCC patients responding to the combination therapy of efti and pembrolizumab; favourable duration and depth of responses, with 5 Complete Responses and a minimum duration of response extended to greater than 9 months across all responding patients; responses continue to be seen in PD-L1 low and high expressors, Further data from TACTI-002 is expected to be reported in H1 2022.

08:49 EST JCP opposed to proposed increase in authorized shares at Farmer Bros. - JCP Investment Management, a significant stockholder of Farmer Bros, with ownership of approximately 4.3% of the Company's outstanding shares, today stated its opposition to Farmer Bros.' proposal to amend its Certificate of Incorporation to increase the number of authorized shares at the Company's upcoming 2021 annual meeting of stockholders scheduled to be held on December 15, 2021. Proposal 3 at the 2021 Annual Meeting seeks stockholder approval to increase the number of authorized shares of common stock of the Company from 25 million to 50 million. We had already privately expressed our concerns to the Company regarding recent dilution of stockholders, so naturally we were alarmed by the proposed increase in authorized shares that could result in extreme dilution of existing stockholders and serve as an anti-takeover measure. In our view, the Company's underperformance over the last 3-, 5-, 10- and 15-year periods coupled with its current high burn rate of 4.2% does not warrant an increase of this magnitude. 1, 2 To put things in perspective, the Company's current market capitalization is approximately $150 million and it filed a shelf registration statement to offer the sale of up to $175 million in securities.Accordingly, JCP intends to vote AGAINST Proposal 3 at the 2021 Annual Meeting and believes that all stockholders of the Company should vote AGAINST Proposal 3.

08:47 EST Patriot National, American Challenger enter merger agreement - Patriot National Bancorp and American Challenger Development announced that they have entered into a definitive agreement under which Patriot will acquire American Challenger via a reverse subsidiary merger, with American Challenger surviving as a wholly owned subsidiary of Patriot. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, American Challenger common stockholders will receive shares of Patriot common stock as consideration and American Challenger preferred stockholders will receive cash. The Merger will create a purpose-driven, digital-first national bank with highly efficient operations to generate industry leading financial performance and a technology driven banking experience that will offer competitive rates and a premium customer experience. Patriot also announced today that it has entered into separate definitive agreements with certain investors, consisting of a private placement in an aggregate principal amount of approximately $540 million of newly issued Patriot voting and non-voting common stock priced at $17.69 per share, warrants for the purchase of non-voting common stock of Patriot, and preferred stock of Patriot Bank. Patriot intends to raise an additional principal amount of at least $350 million, for a total capital raise of at least $890 million, and intends to negotiate and enter into definitive agreements with other investors for the purchase of subordinated debt securities and preferred stock of Patriot in addition to further sales of Patriot common stock and warrants for the purchase of Patriot non-voting common stock (collectively, the "Recapitalization," and together with the Merger, the "Proposed Transactions"). Pursuant to the terms and conditions of the Investment Agreements and the Merger Agreement, the Recapitalization and the Merger will be completed on the same day. Following the Merger, Patriot Bank will adopt the American Challenger business plan and will operate as two divisions - the Patriot Bank Division, which will continue to operate Patriot Bank's existing business, and the American Challenger Division, which will execute the high-growth American Challenger business plan. As soon as practicable following the closing of the Proposed Transactions, Patriot Bank will adopt American Challenger's proprietary technology platform for its operations. This should allow Patriot Bank to operate with a technology cost structure that is largely fixed, in contrast to the typical, more variable cost structure at most banks. Patriot Bank expects this cost structure to drive efficiencies and allow it to share the benefits with customers by offering competitive rates on its products and a differentiated, premium customer experience. This will include connecting with customers via video, account opening and funding initiation in less than a minute, as well as mortgages that close in as little as 20 days. The Proposed Transactions have been approved by the boards of directors of Patriot and American Challenger and are expected to close in the first quarter of 2022, subject to the satisfaction of customary closing conditions, including receipt of required regulatory approvals and approval by Patriot's shareholders. Separately, American Challenger is also announcing today it has entered into a term sheet, which, subject to agreement on definitive documentation, would result in a strategic partnership with Sunlight Financial LLC, the subsidiary of Sunlight Financial Holdings Inc., a leading financing platform for U.S. residential solar and energy-efficient home improvement projects, with respect to a new, multi-year loan purchase program for up to $1.75 billion. The program will focus on loans for solar energy systems, as well as battery storage, to help further accelerate the adoption of clean energy in homes across the United States. Scherzer said, "As a responsible, full-service digital bank, we will be focused on lending in ways that help communities and the planet, with the intent of investing over half of its assets in support of sustainability, local community, and good health." Highlights of the Proposed Transactions: Following completion of the Merger, taking into account the shares issued in the Recapitalization, former American Challenger shareholders will collectively own approximately 13.8% of the combined company, and existing Patriot shareholders will own approximately 8.2% of the combined company. The implied total transaction value of the Merger is approximately $119 million. American Challenger common shareholders will receive 4,092 shares of Patriot common stock for each American Challenger common share they own, and American Challenger preferred shareholders will receive an amount in cash equal to $75,413.22 per share plus any accrued and unpaid dividends on the American Challenger preferred stock. Following closing of the Merger, Patriot will continue to trade under the ticker PNBK. Key members of American Challenger's management team and board of directors will join Patriot upon completion of the Merger. Michael Carrazza, Patriot's current Chairman, will remain a director of Patriot following the Merger. Immediately prior to the completion of the Merger and the Recapitalization, Patriot will change its jurisdiction of Delawar. As of the date of this announcement certain investors, including funds associated with Oaktree Capital Management, L.P. ("Oaktree") and Angelo, Gordon & Co., L.P. ("Angelo, Gordon"), have entered into separate Investment Agreements with Patriot in connection with the Recapitalization. Patriot will enter into additional Investment Agreements for the remainder of the $890 million capital raise with additional investors. In the Recapitalization, Patriot expects to issue approximately: $464.5 million of Patriot voting common stock at $17.69 per share; $95.5 million of Patriot non-voting common stock at $17.69 per share; $70 million aggregate liquidation preference of Patriot preferred stock at $25 per share; $180 million aggregate liquidation preference of Patriot Bank preferred stock at $1,000 per share; Warrants to purchase up to 3.3 million shares of Patriot non-voting common stock; and $80 million aggregate principal amount of ten-year fixed-to-floating rate subordinated notes eligible for Tier 2 regulatory capital treatment. Of this amount, it is anticipated that approximately $12 million will be used to refinance Patriot's currently outstanding senior notes. Following completion of the Recapitalization, taking into account the shares issued in the Merger, participating investors will collectively own approximately 71.8% of Patriot. Certain investors, including Oaktree and Angelo, Gordon, each separately have the right to nominate a director for election to Patriot's board of directors and, subject to approval by Patriot's stockholders, will join Patriot's board of directors upon completion of the Recapitalization.

08:46 EST Asure Software CFO John Pence buys 10,000 shares for $8.75 per share

08:44 EST AstraZeneca says AZD8601 met primary safety, tolerability endpoints in Phase 2a - AstraZeneca (AZN) reports "positive" Phase IIa results from the EPICCURE trial demonstrated that AZD8601 met the primary endpoint of safety and tolerability in patients with heart failure. In the trial, researchers injected mRNA encoding vascular endothelial growth factor, or VEGF-A - known as AZD8601 - directly into the myocardium of patients undergoing elective coronary artery bypass surgery surgery. AZD8601 is being co-developed with Moderna (MRNA). In the study of 11 patients, seven were treated with AZD8601 and four received placebo injections. Trends were observed in the three exploratory efficacy endpoints: left ventricular ejection fraction; NT-proBNP, a biomarker which measures the level of a hormone and is elevated in patients with heart failure; and functional patient reported outcomes, compared with placebo. Results from the EPICCURE trial were presented on 15 November 2021 at the American Heart Association's Scientific Sessions 2021. Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: "Over one billion heart cells can be lost during a heart attack. These early results indicate the potential of mRNA therapeutics in stimulating VEGF-A production to provide reparative and disease-modifying options for patients with heart failure and other ischaemic vascular diseases."

08:42 EST Heidrick & Struggles appoints Heaton as Chief Legal Officer, Corporate Secretary - Heidrick & Struggles (HSII) announced it has appointed Tracey Heaton as its new Chief Legal Officer and Corporate Secretary, effective immediately. Previously, Heaton served as Senior Vice President, Chief Corporate Counsel for Visa (V).

08:41 EST Mayfair Gold expands Fen-Gibb drill program to 80,000 meters - Mayfair Gold announced the significant expansion of the ongoing drill program at its flagship 100%-controlled Fenn-Gib gold project located in the Timmins region of Northeast Ontario. The Fenn-Gib deposit currently hosts a pit-constrained Indicated Resource of 2.08M ounces with disseminated gold mineralization striking east-west on the Pipestone Fault over 1.25 kilometers and up to 300 meters wide. The 30,000m Phase 2 drill program will be supported by three drill rigs and is expected to be completed in the second quarter of 2022. Subject to the timely receipt of assay results, Mayfair expects to report an updated NI 43-101 mineral resource for Fenn-Gib during the third quarter of 2022, with a preliminary economic assessment planned for the fourth quarter of 2022. Mayfair's infill and expansion drill program has been focused on five areas at the Fenn-Gib deposit: Infill drilling within the current resource area to reduce drill hole spacing within the current conceptual open pit to a maximum of 50m; Expansion drilling below the shallow area of the current conceptual open pit in the center and east of the deposit; Expansion drilling to the east of the current conceptual open pit; Infill and expansion drilling for potential underground resources across the full strike of the Fenn-Gib deposit; and Infill and expansion drilling at the high-grade Footwall Zone in close proximity to the north of the Fenn-Gib deposit. Mayfair is also pleased to report that the metallurgical test work program is progressing on schedule. Sample intervals from seven different locations were selected to align with the average modelled annual grades from the potential mine schedule. Five samples were taken from the Fenn-Gib deposit: one from the Footwall Zone that lies within the conceptual open pit, and one from the Footwall Zone outside the conceptual pit. The Company has retained Ausenco Engineering Canada Inc. to manage the metallurgical program in preparation for a Preliminary Economic Assessment. The metallurgical samples are being processed at SGS Canada Inc., located in Lakefield, Ontario, which has over eighty years of metallurgical testing experience. The results will be reported when they are received.

08:39 EST Moderna announces data from AstraZeneca-led CABG trial - Moderna (MRNA) announced data from the AstraZeneca-led (AZN) Phase 2 study evaluating the use of an mRNA therapeutic that encodes for vascular endothelial growth factor-A, or VEGF-A, in patients undergoing coronary artery bypass grafting, or CABG. These data were presented today at the American Heart Association's Scientific Sessions 2021 annual meeting. The Phase 2 study met the primary endpoint of safety and tolerability of AZD8601. In the study of 11 patients, seven were treated with AZD8601 VEGF-A mRNA and four received placebo injections. Numerical trends were observed in endpoints in the heart failure efficacy domains compared with placebo, including increase in left ventricular ejection fraction and patient reported outcomes. In addition, all seven patients treated with AZD8601 had NT-proBNP levels below heart failure limit at six months follow-up compared to one of four patients treated with placebo.

08:38 EST Restaurant Brands to acquire Firehouse Subs for $1B in all-cash transaction - Restaurant Brands International and Firehouse Restaurant announced that they have reached an agreement for RBI to acquire Firehouse Subs for $1B in an all-cash transaction. Jose Cil, Chief Executive Officer of RBI commented, "Firehouse Subs is a special brand with a talented team, impressive culture and community focus that resonates with guests and closely aligns with our core values at RBI. We see tremendous potential to accelerate U.S. and international growth at Firehouse Subs with RBI's development expertise, global franchisee network and digital capabilities. We are excited to welcome the Firehouse Subs team to the RBI family and to continue our ambitious dream of building the world's most loved restaurant brands." Under the terms of the agreement, RBI will acquire Firehouse Subs for $1B in an all-cash transaction. RBI plans to fund the acquisition through a combination of cash on hand and debt. The transaction is expected to close in the coming months subject to satisfaction of customary closing conditions and regulatory approvals. Following the closing of the transaction, Firehouse Subs will remain based in Jacksonville, Florida, and will continue to be managed by Chief Executive Officer, Don Fox, and Chief Financial Officer, Vincent Burchianti.

08:38 EST Burry tweets Musk 'just wants to sell' Tesla - Michael Burry, the head of Scion Asset Management and investor of "The Big Short" fame, tweeted: "Let's face it. @elonmusk borrowed against 88.3 million shares, sold all his mansions, moved to Texas, and is asking @BernieSanders whether he should sell more stock. He doesn't need cash. He just wants to sell $TSLA." Reference Link

08:36 EST Surgery Partners announces closing of public offering of common stock - Surgery Partners announced the closing of its previously announced underwritten public offering of 6,900,000 shares of its common stock at a public offering price of $46.50 per share, which includes 900,000 shares of common stock issued upon the exercise, in full, by the underwriters of an option to purchase additional shares from Surgery Partners. The gross proceeds from the offering, before deducting the underwriter discounts and commissions and other offering expenses, were approximately $320.9 million. Surgery Partners intends to use its net proceeds from the public offering for general corporate purposes, which may include, but is not limited to, funding acquisitions, repaying indebtedness, capital expenditures and funding working capital.

08:35 EST Lazydays appoints Harsh Uchariya as its Chief Information Officer - Lazydays, The RV Authority, announces that Harsh Uchariya has joined the company as its Chief Information Officer, CIO. Uchariya joins Lazydays from ClubCorp, where he was CIO.

08:35 EST Lexagene Holdings appoints Jane Sykes to board of directors - LexaGene Holdings announced Dr. Jane Sykes, BVSc, PhD, MBA, DipACVIM has joined the LexaGene Board of Directors. Dr. Sykes is the Executive Director of Innovation and Entrepreneurship, School of Veterinary Medicine at the University of California, Davis and Professor of Small Animal Internal Medicine.

08:33 EST Tabula Rasa announces five-year contract extension with Rocky Mountain PACE - Tabula Rasa HealthCare announced a five-year contract renewal with Rocky Mountain PACE, RMP, a Program of All-Inclusive Care for the Elderly, PACE, sponsored by Rocky Mountain Health Care Services of Colorado serving more than 800 participants in Colorado Springs. As they expand their program, Rocky Mountain PACE will continue to rely on TRHC's CareKinesis pharmacy and personalized medication management services. Premium Door2Door delivery services, which include voice and text shipping notifications with tracking ability, helps to ensure RMP's participants receive their medications on time.

08:31 EST Genasys board member Daniel McCollum departs - Genasys announced that effective November 11, 2021, Daniel McCollum resigned from the Board of Directors and all Board committees on which he serves, and joined the Company's Strategic Advisory Board.

08:31 EST Inovio to give eight presentations at IPVC - INOVIO announced that eight company-sponsored presentations will be given this week at the 34th International Papillomavirus Conference, IPVC , which is being held virtually from today, November 15 through Friday, November 19. "The IPVC meeting provides INOVIO with an exciting opportunity to showcase our work to develop treatments for HPV-driven diseases, as well as to advance the understanding of the epidemiology and standard of care in these disease states," said Jeffrey Skolnik, M.D., SVP, Clinical Development at INOVIO. "These data highlight our continued commitment to developing medicines, technologies and solutions to help address the unmet needs of patients across the spectrum of HPV diseases." The following INOVIO-sponsored data will be presented at IPVC 2021: VGX-3100 for the Treatment of HPV16/18 Related Cervical HSIL: Results from a Phase 3 Study; Results of VGX-3100 for the Treatment of HPV16/18 Associated Vulvar HSIL: Phase 2 Open-Label Trial Efficacy and Safety Results; VGX-3100 for the Treatment of HPV16/18 Attributable Anal HSIL: Results of a Phase 2 Study; Evaluation of INO-3107 - A Novel DNA Immunotherapy for the Treatment of HPV6/11 Associated Recurrent Respiratory Papillomatosis; Cervical HSIL - U.S. Burden and Comprehensive Assessment of Standard of Care Effectiveness and Safety, 2008-2018: The EACH-WOMAN Project; Vulvar High-Grade Squamous Intraepithelial Lesion: U.S. Epidemiology burden in the Post-HPV Vaccine Introduction Era, 2015-2019; Anal High-Grade Squamous Intraepithelial Lesion: U.S. Epidemiology Burden in the Post-HPV Vaccine Introduction Era, 2015-2019; and Recurrent Respiratory Papillomatosis - All-Ages U.S. Prevalence in 2018.

08:29 EST Realty Income completes spin-off of Orion Office REIT - Realty Income (O), The Monthly Dividend Company, announced it has completed the spin-off of substantially all of its office assets into a new independent, publicly traded REIT called Orion Office REIT. Orion is listed on the New York Stock Exchange under the symbol "ONL." Under the terms of the spin-off, Realty Income stockholders received one share of Orion common stock for every ten shares of Realty Income common stock held as of the record date of November 2, 2021. Realty Income common stockholders will receive cash in lieu of any fractional shares they would otherwise have been entitled to receive in the distribution. Since November 1, 2021, Orion shares have traded on a "when issued" basis on the NYSE under the symbol "ONL.WI." The "when issued" trading of Orion ended at the close of the market on November 12, 2021. Starting today, the "regular way" trading of Orion common stock will begin on the NYSE under the symbol "ONL." Shares of Realty Income will continue to trade under the symbol, "O."

08:28 EST IKONICS, TeraWulf announce registration statement filed, meeting for vote - TeraWulf and IKONICS (IKNX) announced that the registration statement on Form S-4, which includes a definitive proxy statement/ prospectus, filed with the Securities and Exchange Commission in connection with their previously announced business combination was declared effective by the SEC on November 12, 2021. A special meeting of IKONICS shareholders to vote on the business combination, among other matters, is scheduled to be held virtually at 8:00 a.m., central time, on December 10, 2021. "We are pleased to reach this next phase on our path to launch as a publicly listed company and bring our new paradigm for cryptocurrency mining to the public markets," said Paul Prager, Chairman and Chief Executive Officer of TeraWulf. "Since announcing the transaction with IKONICS in June 2021, we've continued to take steps to develop our facilities in New York and Pennsylvania and towards our goal of providing domestically produced bitcoin powered by 100% zero-carbon energy. Our team brings decades of energy experience and with it a model for sustainable, large-scale crypto currency mining, which we believe will create substantial long-term value for our shareholders." Concurrent with the completion of the business combination, which is expected to occur by the end of 2021 subject to approval by IKONICS shareholders and the satisfaction of other customary closing conditions, Telluride Holdco, Inc., the ultimate parent company of TeraWulf and IKONICS, is expected to be renamed "TeraWulf Inc.", and its shares of common stock are expected to be listed on The Nasdaq Stock Market LLC under the trading symbol "WULF."

08:26 EST Farmmi's subsidary wins another product order - Farmmi announced the Company's subsidiary Zhejiang Farmmi Biotechnology won another new product order. The latest order is for dried black fungus. The customer will export Farmmi's products to Vancouver, Canada. Yefang Zhang, Farmmi's Chairwoman and CEO, commented, "We continue to execute on our multi-pronged growth strategy, as we leverage our brand, premium agriculture product line, and global supply chain relationships. We have benefited from steady growth in 2021 and expect year over year growth compared to 2020, with 2022 even better based on customer demand indications. At the same time, we remain focused on unlocking value as we help Farmmi realize its true potential."

08:24 EST Redfin announces it has launched in two new locations - Redfin announced it has launched in Big Bear, CA and Ocean City, MD and extended its brokerage services in Hudson Valley, NY to include parts of Ulster County. In these markets, consumers can now buy and sell homes with local Redfin agents and use Redfin's website and mobile app to search for homes for sale, book on-demand home tours, and track their home's estimated value with the Redfin Estimate.

08:23 EST Tricida raises $42M in registered direct equity financing - Tricida announced that it has entered into definitive agreements with certain investors for the purchase and sale of common stock, pre-funded warrants and common warrants in a registered direct equity financing for gross proceeds to Tricida of approximately $42 million. Deep Track Capital is leading the Financing, with participation from Frazier Life Sciences, OrbiMed and a member of the company's management team. The Financing is expected to close on or about November 15, 2021, subject to customary closing conditions. The Financing includes the issuance and sale of an aggregate of 4,666,667 shares of Tricida common stock at $6.00 per share, pre-funded warrants to purchase up to 2,333,333 shares of common stock, and the issuance of common warrants to purchase 7 million shares of common stock. The pre-funded warrants were issued at a price of $6.00 per share of common stock purchasable and have an exercise price of $0.001. The common warrants have an exercise price of $11.00 per share. The $6.00 price per each common stock share and pre-funded warrant and the $11.00 per share exercise price for each common warrant represent a 28% and 134% premium, respectively, to the company's 30-day volume weighted average share price of $4.69 per share and a 10% and 101% premium, respectively to the closing price of $5.46 on November 12, 2021. The common warrants may be exercised for shares of common stock or, in certain circumstances as described in the warrants, pre-funded warrants, at any time on or after the date that is six months after the date of issuance until its expiration date, which will be the earliest of: (a) the third anniversary of the date of issuance, immediately prior to the closing of certain fundamental transactions or (c) five business days after written notice following certain events, including (i) submission of the Company's new drug application for veverimer with the U.S. Food and Drug Administration (FDA), or (ii) following the issuance of a press release reporting the results of the primary analysis of the VALOR-CKD trial, the completion of a common stock financing resulting in not less than $75 million in gross proceeds at an offering price of not less than $13.50 per share, or the VWAP of the Company's common stock is greater than $15.00 per share with certain multiple-day trading volume requirements. Net proceeds from the Financing are expected to be approximately $41.4 million. These net proceeds will be used to fund corporate operations, including the VALOR-CKD renal outcomes trial, and are expected to extend Tricida's financial runway into the first quarter of 2023. Tricida estimates that the additional financial resources will enable it to conduct the previously announced administrative stop of the VALOR-CKD trial in the second quarter of 2022 and enable the accrual of primary endpoint events until approximately July 2022. Based on Tricida's historical rate of accrual of primary endpoint events of about 10 to 12 events per month, Tricida believes that this date corresponds to approximately 240 to 255 primary endpoint events. Based on current estimates, Tricida anticipates reporting topline results from the VALOR-CKD trial in the third quarter of 2022 and believes that, with the proceeds of today's financing, its financial resources will extend for approximately six months following the anticipated announcement of top-line results from the VALOR-CKD trial.

08:22 EST Bioventus CFO Greg Anglum stepping down - Bioventus CFO and Senior VP Greg Anglum is transitioning from his role to pursue other career opportunities. To ensure a smooth transition, Anglum will remain in his current role until a successor is named. Bioventus has been actively working with Spencer Stuart to identify a successor to Anglum. Anglum's departure is unrelated to Bioventus' business performance, financial reporting, or controls, and the company is reaffirming its previously issued 2021 financial guidance.

08:21 EST OneConnect completes internal investigation - OneConnect announced that the company's audit committee has completed the internal investigation and found no evidence to support the allegations in the anonymous complaint disclosed in the press release issued by the company on August 31. As previously disclosed, the Audit Committee initiated the internal investigation immediately on August 24, four days after the company became aware of these allegations. Based on the work and procedures carried out under its supervision, the audit committee has concluded that the findings from the internal investigation do not substantiate the allegations.

08:19 EST Medipharm Labs announces start of Bryan Howcroft as CEO - The company said, "We are delighted to welcome our new CEO to MediPharm, effective today, Mr. Bryan Howcroft. Mr. Howcroft's deep expertise in navigating complex regulated international markets will enable MediPharm's transition towards pharmaceutical and medical markets to reach new heights."

08:17 EST Prospect Capital says preferred stock offerings exceeded $400M - Prospect Capital Corporation announced that Prospect's preferred stock offerings have exceeded $400 million in aggregate liquidation preference issuances since the initial closing in the quarter ending December 31, 2020.

08:16 EST Casper Sleep to be acquired by Durational Capital for $6.90 per share - Casper Sleep announced that it entered into a definitive agreement to be acquired by Durational Capital. Under the terms of the agreement, Casper common stockholders will receive cash consideration of $6.90 per share, representing a 94% premium to the closing share price on November 12, the last trading day prior to this announcement and a premium of approximately 80% to the 30-day volume weighted average price ending November 12. Casper's board of directors has unanimously approved the transaction and recommends that Casper stockholders approve the transaction and adopt the merger agreement. The transaction is expected to close in Q1 of 2022 and is subject to customary closing conditions, including Casper stockholder approval. Officers and directors of Casper and affiliated investors, who in the aggregate own or control approximately 28% of the company's outstanding shares, have agreed to vote in favor of the transaction. Upon closing the transaction, Casper will operate as a privately-held company and will remain based in New York.

08:14 EST Lattice Semiconductor acquires Mirametrix, terms unidsclosed - Lattice Semiconductor announced it has acquired Mirametrix, a software company focused on advanced artificial intelligence, or AI, solutions for computer vision applications, in an all-cash, accretive transaction. Mirametrix software has been deployed in more than 20M end user systems worldwide.

08:14 EST Lear to supply connectivity, vehicle positioning solutions to EV automaker - Lear announced it will begin supplying its 4G/5G telecommunications unit in late 2022 to a global electric vehicle automaker to provide advanced connectivity and vehicle positioning solutions that assist driving and parking functions. This is a new automotive production application of Lear's proprietary Global Navigation Satellite System integrated into Lear's 4G/5G telecommunications unit, which connects the vehicle to cloud services and controls diagnostics and communications to and from the vehicle. "Our global customers are seeking innovative solutions that provide market-leading safety and consumer experiences," said Carl Esposito, Lear Senior Vice President and President, E-Systems. "This award validates our unique value proposition of offering a telecommunications unit integrated with precise vehicle positioning solutions."

08:13 EST Sangoma Technologies files final base shelf prospectus - Sangoma Technologies is pleased to announce that on November 12, 2021 it filed and obtained a receipt for its final short form base shelf prospectus with the securities regulatory authorities in each of the provinces of Canada, other than Quebec. The base shelf prospectus will allow Sangoma to qualify the distribution by way of prospectus in Canada of up to C$200,000,000 of common shares of the Company, debt securities, warrants, subscription receipts, units, or any combination thereof, during the 25-month period that the base shelf prospectus is effective. The specific terms of any offering under the base shelf prospectus will be established in a prospectus supplement, which will be filed with the applicable Canadian securities regulatory authorities in connection with any such offering. There is no certainty that any securities will be offered or sold under the base shelf prospectus within its 25-month period of effectiveness. Concurrent with the filing of the base shelf prospectus, Sangoma withdrew its previous base shelf prospectus dated June 29, 2020.

08:11 EST Agra secures recurring revenue stream via six-month cannabis offtake agreement - Agra Ventures is pleased to announce that its wholly owned subsidiary, Propagation Services Canada Inc. d.b.a. Boundary Bay Cannabis, has signed a Cannabis Purchase Agreement with an arm's length third party. The Offtake Agreement specifies the recurring monthly purchase of a defined minimum quantity of cannabis in dried flower form, with a minimum range of THC content, terpenes and other specifications. Due to the confidentiality clause within the Offtake Agreement, no specific price, volume or other such information can be disclosed by either the Company and its affiliates or by the Purchaser. Subject to other terms and conditions, the Contract has an initial term of six months, with a renewal term of equal length if not terminated by either party, and a delivery date of the first order of cannabis being on or before November 23, 2021. Entering into the Offtake Agreement marks a significant milestone for the Company as it formalizes the ongoing sale of Boundary Bay Cannabis products grown at the Delta greenhouse complex on a wholesale basis for the first time. Importantly, it establishes a new relationship with the Purchaser, which was originally brokered by a separate third party on the Company's behalf. In exchange for establishing the relationship between Boundary Bay Cannabis to the Purchaser, the Company has agreed to pay the Broker an average rate of 4.9 per cent on all sales over the term of the Contract from Boundary Bay Cannabis to the Purchaser.

08:10 EST Splunk reports preliminary Q3 revenue $660M, consensus $646.38M - Reports preliminary Q3 total ARR $2.83B. Reports Q3 non-GAAP operating income margin down 14%. "Thanks to our team's focused execution, we had another excellent quarter and surpassed $1 billion of cloud ARR. We continue to deliver high value to our customers as we see continued momentum in our cloud and business model transformations," said Jason Child, Splunk CFO.

08:08 EST Splunk CEO Doug Merritt steps down, Graham Smith appointed interim CEO - Splunk announced that Graham Smith, chair of Splunk's board of directors, has been appointed interim CEO, effective immediately. Smith succeeds Doug Merritt, who is stepping down after having served as president and CEO for the past six years. Merritt will remain with the company in an advisory role to ensure a smooth transition and as the Board begins its search for Splunk's next CEO. Smith has served as a member of Splunk's board since 2011 and as chair since 2019. As interim CEO, Smith will focus on investments and priorities for the company's upcoming fiscal year to ensure continued customer and cloud transformation success. Smith will retain his chair responsibilities while the Board conducts its search.

08:06 EST Galectin Therapeutics expects cash to fund operations through Mar. 31, 2023 - As of September 30, 2021, the Company had $36.6 million of cash and cash equivalents. On September 17, 2021, the Company received $10 million in proceeds from an unsecured convertible promissory note from its Board Chairman, Richard E. Uihlein. The Company also has an agreement for an additional $10 million unsecured promissory note from Mr. Uihlein to close in December 2021. The Company believes it has sufficient cash to fund currently planned operations and research and development activities through at least March 31, 2023.

08:05 EST Appili Therapeutics' ph3 PRESECO trial not achieve statistical significance - On Friday, the company announced that its "Phase 3 PRESECO - PREventing SEvere COVID-19 - clinical trial evaluating oral antiviral Avigan/Reeqonus , or favipiravir, for the treatment of mild-to-moderate COVID-19 - did not achieve statistical significance on the primary endpoint of time to sustained clinical recovery. Additional analyses of the trial data are ongoing. The clinical trial enrolled 1,231 patients with mild-to-moderate COVID-19 from 38 study sites across the United States, Mexico, and Brazil."

08:03 EST CHP Merger, Accelus announce proposed business combination - Integrity Implants Inc. d/b/a Accelus, and CHP Merger Corp., a special purpose acquisition company, or SPAC, formed by an affiliate of Concord Health Partners, announced entry into a definitive business combination agreement. Upon the closing of the business combination, CHP Merger Corp. will be renamed Accelus. The business combination is expected to be completed in early 2022. Based in Palm Beach Gardens, Florida, and established through the combination of Integrity Implants Inc. and Fusion Robotics, LLC, Accelus is a commercial stage medical technology company with a mission to accelerate the adoption of minimally invasive surgery as the standard of care in spine. With a portfolio of MIS spinal implants leveraging its proprietary Adaptive GeometryTM technology and a compact precision robotics platform, Accelus is focused on improving procedures and outcomes, creating favorable economics, and providing broad accessibility across end markets, including ambulatory surgery centers and internationally. On November 14, 2021, CHP Merger Corp. entered into a definitive agreement to combine with Accelus. Upon closing of the business combination, the combined company will have an estimated pro-forma enterprise value of approximately $482 million. The proposed transaction has been unanimously approved by the boards of directors of each of CHP Merger Corp. and Accelus and is subject to the approval of the stockholders of CHP Merger Corp. and Accelus, and the satisfaction or waiver of other customary conditions, including a registration statement on Form S-4 being declared effective by the U.S. Securities and Exchange Commission. The proposed transaction is expected to close in early 2022.

07:59 EST Gilat Satellite selected by Africa Mobile Networks for coverage expansion - Gilat Satellite announced that Africa's largest satellite cellular backhaul network is extending its coverage to a dozen countries in Africa. Africa Mobile Networks has deployed Gilat hubs and placed additional orders of Gilat cellular backhaul terminals to serve multiple Tier-1 Telcos in Africa.

07:58 EST Oyster Point Pharma announces publication of ONSET-2 Phase 3 data - Oyster Point Pharma announced that results from the multicenter, randomized, double-masked, vehicle-controlled Phase 3 clinical trial of TYRVAYA Nasal Spray have been published in Ophthalmology.1 TYRVAYA Nasal Spray 0.03 mg is a highly selective cholinergic agonist that is FDA-approved to treat the signs and symptoms of dry eye disease as a multidose nasal spray. "This Phase 3 study of TYRVAYA nasal spray shows consistent outcomes as compared to the ONSET-1 Phase 2b trial. These results show clinically meaningful improvements in basal tear film production," said Jeffrey Nau, Ph.D., MMS, President and Chief Executive Officer of Oyster Point Pharma. Dr. Nau continued, "These results are notable as TYRVAYA is the first and only cholinergic agonist nasal spray approved by the FDA to treat patients with the signs and symptoms of dry eye disease, leveraging this novel mechanism of action of activating the trigeminal parasympathetic pathway."

07:57 EST Orgenesis enters collaboration agreement with medical center in Tel Aviv - Orgenesis has entered into a collaboration agreement with Tel Aviv Sourasky Medical Center to establish a point-of-care cell therapy center at the Ichilov Hospital, a multidisciplinary healthcare institution in Israel. The parties plan to conduct collaborative cell-based research projects, initially focused on advancing the clinical development and validation of Orgenesis' CD19 CAR-T therapies, including CAR-T derived exosome products, utilizing Orgenesis' proprietary T-cell culturing and point-of-care processes and systems. The parties also plan to deploy Orgenesis Mobile Processing Units and Labs onsite to support joint research and validation activities for advanced cell and gene therapies developed by both Orgenesis and the Tel Aviv Sourasky Medical Center.

07:56 EST Ginkgo Bioworks expects to add 9 programs in Q4 of 2021 - For a total of 30 new programs this year. Ginkgo expects total Foundry revenue of at least $100 million for full year 2021, inclusive of both downstream value share and services revenue.

07:54 EST Kala Pharmaceuticals announces time change for Q3 results - Kala Pharmaceuticals announced that it has changed the time of its previously scheduled financial results conference call and live audio webcast. The Company will now report its third quarter 2021 financial results and provide a business update on Monday, November 15th at 10:30 am. ET.

07:53 EST Rhythm Pharmaceuticals' sNDA for Imcivree accepted by FDA - Rhythm Pharmaceuticals announced that the FDA has accepted for filing the company's supplemental New Drug Application - sNDA - for Imcivrree, a melanocortin-4 receptor agonist, for patients with Bardet-Biedl syndrome or Alstrom syndrome. The FDA granted Priority Review of the sNDA and assigned a Prescription Drug User Fee Act goal date of March 16, 2022. BBS and Alstrom syndrome are ultra-rare genetic diseases that affect multiple organ systems.

07:53 EST Novocure reports updated data from 2-THE-TOP trial - Novocure announced that David Tran, chief of the division of Neuro-Oncology at the McKnight Brain Institute at the University of Florida, has released updated data from the phase 2 pilot 2-THE-TOP trial testing the safety and efficacy of Tumor Treating Fields, or TTFields, together with pembrolizumab and temozolomide for the treatment of adult patients with newly diagnosed glioblastoma, or GBM. In patients with greater than nine months of follow-up, median progression-free survival, the primary endpoint, was at least 11.2 months. Overall, 24% of patients achieved partial to complete response. Tran will present these data at the Society for Neuro-Oncology, or SNO, 2021 Annual Meeting in Boston on November 19. Twenty-five patients with a median age of 61 years were enrolled in the 2-THE-TOP study, with a median follow-up of 14.7 months. Eight had biopsy only and partial resection, respectively. Eighteen had unmethylated MGMT and 3 had an IDH mutation. Twelve were progression-free, and 15 were still alive. Of the 19 patients with follow-up greater than 9 months, the median progression-free survival was at least 11.2 months compared to 6.7 months from the historical control study, EF-14, in which patients received TTFields and adjuvant temozolomide. Six patients with measurable tumors achieved partial or complete response. 193,760 peripheral blood mononuclear cells were sequenced in 12 patients before pembrolizumab and detected robust post-TTFields T cell activation in 11 of 12 patients via the T1IFN trajectory with a strong correlation with the TCRass clonal expansion Simpson index. The study defined a T cell-based gene signature of TTFields effects on TCRass clonal expansion. The most common adverse events were thrombosis, seizure and metabolic disturbances. The 2-THE-TOP trial is a phase 2 pilot trial designed for the treatment of patients with newly diagnosed GBM. Patients enrolled in the trial underwent maximal tumor resection followed by standard chemoradiation. Following the completion of chemoradiation, patients began a course of monthly cycles of adjuvant temozolomide. Treatment with TTFields started at approximately the same time as the first cycle of adjuvant temozolomide. Pembrolizumab was introduced in the second cycle of treatment and subsequent cycles of pembrolizumab were administered every three weeks until first disease progression or unacceptable toxicities or 2 years, whichever comes first.

07:51 EST Tecnoglass upsizes revolving credit facility, extends maturity date - Tecnoglass announced it has amended its senior secured revolving credit facility to increase the borrowing capacity under its committed Line of credit from $50 million to $150 million , reduce its borrowing costs by an approximate 130 basis points, and extend the initial maturity date by one year to the end of 2026. Borrowings under the credit facility will now bear interest at a rate of LIBOR with no floor plus a spread of 1.75%, based on the Company's net leverage ratio, compared to a prior rate of LIBOR with a floor of 0.75% plus a spread of 2.50%. The company expects the amendments to provide approximately $3 million of incremental interest expense savings on an annual basis at current outstanding borrowings.

07:50 EST Kaixin Auto says POCCO EV sales exceed 20,000 units - Kaixin Auto Holdings announced that according to Henan Yujie Times Automobile Co., Ltd., which signed a binding M&A term sheet with Kaixin in August 2021, the sales volume of its POCCO electric vehicle models in October reached 8,661 units, of which sales of the DuoDuo and MeiMei models accounted for 5,627 and 3,034 units respectively, a 33.7% and 12.2% increase over September. As of October, total sales of POCCO EV models exceeded 20,000 units. According to data released by the China Association of Automobile Manufacturers, China's auto sales in October were 2.33 million units. New energy vehicles performed strong, whose production and sales reached a record high of 397,000 and 383,000 units in October respectively, an increase of 12.5% and 7.2% over the previous month. Mr. Mingjun Lin, Chairman and CEO of Kaixin said: "Mini cars and mid-size cars have become the two main stream models of new energy vehicle sales in China. This year marks a turning point for China's new energy vehicles to transform from policy-driven to market-driven."

07:49 EST MAG Silver secures $40M revolving credit facility - MAG Silver is pleased to report the signing of a binding commitment letter with the Bank of Montreal for a fully underwritten $40 million revolving credit facility. Closing of the Facility is expected to occur by mid-December 2021 and is subject to the satisfaction of customary conditions, and completion of definitive documentation. The Facility has a maturity date of December 31, 2024 and will be available for working capital and general corporate purposes, and provides MAG with additional liquidity and financial flexibility for its 44% share of the Juanicipio development and exploration costs should it be needed.

07:48 EST The Real Brokerage appoints Raj Naik as Chief Operating Officer - The Real Brokerage announced that Raj Naik will join its management team as Chief Operating Officer. Naik will be responsible for driving operational efforts, growth initiatives, and transforming the service level offered to the agents supported by Real's technology platform. Naik has been an entrepreneur and technologist for over 20 years. Naik joins Real from Workrise, previously RigUp, a workforce management platform for the skilled trades, where he served as Managing Director for its construction business unit and was a member of the executive leadership team.

07:47 EST Viridian Therapeutics announces FDA clearance of IND application for VRDN-001 - Viridian Therapeutics announced the U.S. Food and Drug Administration clearance of its Investigational New Drug application for VRDN-001, which the Company is developing for the treatment of thyroid eye disease. VRDN-001 is a monoclonal antibody that binds and blocks the IGF-1R signaling pathway with sub-nanomolar affinity. This mechanism of action is clinically and commercially validated for the treatment of TED. The Company's first clinical trial for VRDN-001 is a Phase 1/2 proof of concept trial including multiple randomized, placebo-controlled cohorts of TED patients to assess the potential for VRDN-001 to provide rapid improvement of signs and symptoms of TED, including proptosis. The protocol for this trial allows for additional patient cohorts to assess differing treatment paradigms that may offer advantages over currently available therapies and mitigate patient treatment burden. The Company expects to announce top line data from the proof of concept portion of the trial in the second quarter of 2022.

07:45 EST Digimarc to acquire product cloud company EVERYTHING Limited - Digimarc Corporation announced it entered into a definitive agreement to acquire the Product Cloud company EVRYTHNG Limited in a stock transaction. "This acquisition allows us to provide a complete solution set to our customers," explains Digimarc CEO Riley McCormack. "The best determinant of a technology product's value is how much of the customer's problem it can solve. By combining Digimarc's unique and advanced means of identification with the pioneer and most advanced supplier of product item business intelligence using any means of identification, we are now uniquely positioned to unlock additional solutions for our customers and enhance their Digimarc journey." The acquisition expands the geographic footprint for both companies. EVRYTHNG, based in London with offices in New York, Beijing, Minsk, and Lausanne is finding much success in North America. Conversely, Digimarc, based in the Portland, Oregon area, has a growing customer base across Europe. Digimarc will acquire EVRYTHNG for shares of Digimarc common stock. The proposed transaction is subject to the satisfaction or waiver of certain closing conditions and is expected to close in January 2022.

07:44 EST Palatin expects cash to fund operations through FY22 - As of September 30, 2021, Palatin's cash and cash equivalents were $53.4M with $0.9M of accounts receivable, compared to cash and cash equivalents of $60.1M with $1.6M of accounts receivable, as of June 30, 2021.

07:42 EST Molecular Templates expects cash to fund operations into 2H23 - As of September 30, 2021, MTEM's cash and investments totaled $175.4 million. MTEM's current cash and investments are expected to fund operations into the second half of 2023.

07:37 EST Freyr, Glencore sign supply contract for up to 1,500 metric tons of cobalt - Freyr Battery (FREY) and Glencore International (GLNCY), have signed a contract for the supply of up to 1,500 metric tons of high grade, sustainably sourced cobalt metal cut cathodes made from partially recycled cobalt produced at Glencore's Nikkelverk facility in Norway. The supply contract follows the letter of intent between Freyr and Glencore announced on February 9. Cobalt is a core component in Freyr's lithium-ion battery cells, which will be produced at the company's facilities under development in Mo i Rana, Norway. Freyr and Glencore will collaborate closely to minimize their carbon footprint and define actions and milestones to meet the common ambition of 100% carbon neutral material, including the potential use of carbon offsets schemes. The companies will also collaborate to develop a scheme to introduce recycling certificates to document the delivery of recycled material as well as on the collection and processing of battery scrap generated during the production of battery material and cells. The agreement also covers exploring potential collaboration structures between Glencore and Freyr in Norway and around the world. This expanded collaboration targets the supply of nickel to Freyr and the supply of recycling scrap from NCM cells produced by Freyr in line with the timeline for Freyr's planned production of battery cells in Mo i Rana, Norway. Freyr and Glencore will also explore potential collaboration for battery material and battery scrap recycling and work together to assure responsible sourcing and recycling through third-party audits.

07:36 EST Tyson Foods delivered double digit sales, earnings growth during Q4, says CEO - "We delivered double digit sales and earnings growth during the fourth quarter and full year, and our performance was supported by our diverse portfolio and continued strength in consumer demand for protein," said Donnie King, president and CEO of Tyson Foods. "We delivered a record performance in our beef segment and experienced share gains in our retail core business lines, which include our Tyson, Jimmy Dean, Hillshire Farm and Ball Park iconic brands, while supporting the continued recovery in foodservice." King added, "To foster continuous improvement and faster decision making, we're launching a new productivity program designed to deliver more than $1B in annual savings by the end of 2024. The focus of this plan includes operational and functional excellence, digital solutions, and automation and advanced technologies."

07:32 EST Rocket Pharmaceuticals announces updated data from RP-A501 trial - Rocket Pharmaceuticals announced updated data from the Phase 1 clinical trial evaluating a single intravenous infusion of RP-A501, the company's investigational gene therapy, for the treatment of Danon Disease. This update, which includes interim safety and efficacy data from patients in the low-dose and high-dose adult and adolescent cohorts, demonstrates RP-A501 was generally well tolerated at the low-dose and conferred sustained clinical benefit. RP-A501 was generally well tolerated at the 6.7e13 vg/kg dose level. All observed adverse effects were reversible with no lasting sequelae. Early transaminase and creatinine kinase elevations returned to baseline or decreased. As previously disclosed, RP-A501 r-AAV dose-dependent toxicity was seen in one of the two patients treated at the 1.1e14 vg/kg dose level. The affected patient, who received the largest total dose, developed thrombotic microangiopathy, or TMA, that fully resolved with supportive treatment including transient hemodialysis. Across both dose levels, the most common serious adverse event, or SAE, observed was steroid-induced myopathy in three patients which resolved subsequent to corticosteroid discontinuation. Based on the observed safety and efficacy to-date, the Company will focus on the low-dose cohort moving forward and will no longer administer the high-dose to study patients. An updated protocol developed in collaboration with the FDA has been implemented to mitigate development of TMA and other treatment-related adverse events. An improvement in NYHA class was observed in three patients who had closely monitored immunosuppression with follow-up greater than one year and stabilization was observed in one low-dose patient without a closely monitored immunosuppressive regimen. A substantial improvement in B-type natriuretic peptide, a key marker of heart failure, was observed in all three low-dose patients and one high-dose patient. Among the three low-dose patients, BNP decreased from a pretreatment baseline by 57% at 24 months, 79% at 18 months, and 75% at 15 months, respectively. In the high-dose patient, BNP decreased from a pretreatment baseline by 67% at 12 months. In patients with closely monitored immunosuppression left ventricular posterior wall thickness improved and ejection fraction improved or stabilized at 12 to 18 months on echocardiography. Severe and progressive wall thickening is a hallmark of the hypertrophic cardiomyopathy of Danon Disease and is a major contributor to early mortality in male patients. Cardiac output remained normal for all patients with improved or stable left heart filling pressures as measured by cardiac catheterization. Three low-dose patients and one high-dose patient demonstrated improvements in the 6-minute walk test. One low-dose patient improved from a pretreatment baseline of 443 meters to 467 m at 24 months. The second low-dose patient improved from a pretreatment baseline of 405 m to 410 m at 18 months. The third low-dose patient improved from a pretreatment baseline of 427 m to 435 m at 15 months. The high-dose patient improved from a pretreatment baseline of 436 m to 492 m at 12 months. Evidence of sustained cardiac LAMP2B gene expression by immunohistochemistry and Western blot with qualitative improvement of vacuoles and cardiac tissue architecture on electron microscopy was observed at both dose levels. Sustained cardiac LAMP2B gene expression by immunohistochemistry was observed in all three patients with a closely monitored immunosuppressive regimen. Specifically, LAMP2B gene expression by immunohistochemistry in the low-dose was 68% in one patient at Month 12 and 92% in another patient at Month 9. In one patient who received the high-dose, LAMP2B gene expression by immunohistochemistry was 100% at Month 12. As previously disclosed, one patient in the high-dose cohort underwent a heart transplant at Month 5. This patient had advanced disease including diminished LV ejection fraction on echocardiogram and markedly elevated LV filling pressure prior to treatment. His clinical course was characteristic of Danon Disease progression. Analysis of the explanted heart revealed significant fibrosis consistent with advanced Danon Disease. Myocardial tissue from the explanted heart at 5 months post-treatment displayed 100% LAMP2B protein expression by immunohistochemistry throughout non-fibrotic cardiac regions including the ventricles and other essential targeted areas.

07:27 EST Milestone Pharmaceuticals announces presentation of NODE-301 trial of etripamil - Milestone Pharmaceuticals announced new data from a post-hoc analysis of the Phase 3, randomized, double-blind, placebo-controlled NODE-301 trial of etripamil nasal spray, the company's novel investigational, short-acting calcium channel blocker, in patients with paroxysmal supraventricular tachycardia, PSVT. The analysis demonstrated that etripamil significantly decreased heart rate prior to conversion to sinus rhythm. The data were featured in a poster presentation titled, "Etripamil Nasal Spray Reduces Heart Rate in Patients with Paroxysmal Supraventricular Tachycardia Prior to Conversion to Sinus Rhythm," at the American Heart Association Scientific Sessions 2021 held November 13-15, 2021. "I would like to congratulate the study authors and thank our team, the study investigators, and the clinical site colleagues for their hard work in making this analysis possible, and would also like to extend a special thank you to the patients for supporting the etripamil development initiative," said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. "We remain on track to report topline data from the RAPID trial in the second half of 2022, and in parallel, continue to advance the entire etripamil development program. We are committed to elucidating the full potential of etripamil to treat symptomatic episodes of elevated HR associated with these conditions in the at-home setting." The NODE-301 trial, which enrolled a total of 431 patients across 65 sites in the U.S. and Canada, was an event-driven, Phase 3 efficacy trial of etripamil versus placebo for terminating supraventricular tachycardia, SVT, episodes in a medically-unsupervised setting. The analysis assessed the effect of etripamil on HR during the SVT episode and prior to conversion to SR, as well as the correlation of HR with patient-reported outcomes in 150 patients. Patients treated with etripamil experienced a significantly greater reduction in mean HR from baseline within 10 minutes of administration as compared to placebo-treated patients. Self-administration of intranasal etripamil rapidly and significantly decreased HR prior to conversion of SVT to SR, starting within 3 minutes and lasting up to 40 minutes after treatment. with the trend sustained over the 60-minute observation period. Patients presented non-statistically different baseline HRs in the etripamil and placebo groups.

07:24 EST Village Farms acquires 70% of ROSE Lifescience - Village Farms International announced it has acquired 70% ownership of privately-held, Quebec-based, ROSE LifeScience, a branded cannabis producer, supplier and commercialization company in the Province of Quebec, effective today. The transaction is valued at up to C$46.7M. ROSE becomes the Quebec operational unit of Village Farms' Canadian cannabis business segment, with ROSE's headquarters and the existing team remaining in Quebec. Highlights of the Acquisition: Adds a presence in the Province of Quebec as a cannabis supplier, producer and commercialization company in the Province of Quebec; adds experienced, Quebec-based industry leaders who will join the Village Farms/Pure Sunfarms team; and, adds a Quebec-based, 55,000 square foot, Health Canada-licensed Controlled Environment Agriculture cultivation and processing facility, which is included in the transaction.

07:19 EST DuPont breaks ground on new $30M facility in East China - DuPont announced it is breaking ground on its new $30M facility which will produce a range of materials to advance applications for electrification and lightweighting in support of growing demand for its automotive adhesives. "The new facility will offer state-of-the-art process capability and quality, capacity to serve regional needs, excellent access to transportation for shipping and logistics advantages and technical support to help ensure a world-class customer experience," the company said. It will be built at the Yangtze River International Chemical Industrial Park in the Zhangjiagang Free Trade Zone and is expected to be fully operational by early 2023. "As an important milestone in DuPont's history, this investment reinforces our commitment to advance auto electrification and sustainability while strengthening our leadership in China and the Asian market," said Tina Wu, Global Vice President, Advanced Solutions for DuPont Mobility & Materials. "This new manufacturing facility will produce industry-leading innovative products to support our auto customers as they transition to electric and hybrid vehicles."

07:19 EST Six Flags CEO Michael Spanos steps down, Selim Bassoul succeeds - Six Flags (SIX) announced that Selim Bassoul, formerly the non-executive chairman of the board, has been appointed CEO and president of Six Flags. Effective immediately, Bassoul will replace Michael Spanos, who has stepped down after two years of service, as CEO, president and a member of the board. Bassoul will continue to serve as a member of the board, and Ben Baldanza, an independent director of Six Flags, and former CEO of Spirit Airlines (SAVE), has been elected as the new non-executive chairman of the board.

07:16 EST Qilian International initiates development of new drug for gastric cancer - Qilian International announced that the company recently started, through its subsidiary Gansu Qilianshan Pharmaceutical, developing a new drug, Vitacoenzyme, that aims to prevent gastric cancer. Currently, Gansu QLS is in the process of selecting and cultivating fungal strain. The Drug is expected to be on the market within three years. Vitacoenzyme is a therapeutic and nutritional compound designed to promote cell growth, improve immunity, enhance the activity of detoxification enzymes, prevent abnormal lipid metabolism, increase the decomposition rates of many carcinogens in human bodies, and promote excretion from human bodies. Vitacoenzyme has also shown some positive effect on interfering and blocking carcinogenesis and preventing cancer in the upper gastrointestinal tract. At present, Vitacoenzyme is primarily used for treatment of chronic gastritis, atrophic gastritis, superficial gastritis, esophagitis, esophageal epithelial cell hyperplasia, prevention of cancer due to cell hyperplasia, as well as the adjuvant treatment of various types of hepatitis and the treatment of riboflavin deficiency and other diseases with remarkable clinical efficacy. Zhanchang Xin, Chairman of the Board of Directors and CEO of the Company, commented, "The development of this Drug is based on our observation that we believe the future market trend for it is upward with tremendous demand potential. Thus, we will spare no effort to conduct research and development on this Drug to meet its market demand in the future and further serve the public health. More importantly, we expect that after the launch of this Drug, it could significantly contribute to the improvement of our production capacity and performance in the future."

07:14 EST Amplify Energy rescinds 2021 guidance due to Southern California oil spill - On October 2, 2021, contractors operating under the direction of Beta Operating Company, a subsidiary of Amplify, observed an oil sheen on the water approximately four miles off the coast of Newport Beach, California. Beta platform personnel were notified and promptly initiated the Company's Oil Spill Response Plan, which was reviewed and approved by the Bureau of Safety and Environmental Enforcement's Oil Spill Preparedness Division within the United States Department of the Interior, and which included the required notifications of specified regulatory agencies. On October 3, 2021, a Unified Command, consisting of the Company, the U.S. Coast Guard and California Department of Fish and Wildlife's Office of Spill Prevention and Response, was established to respond to the Incident. The Company is and has been fully committed to working cooperatively within the Unified Command and with all relevant agencies to respond to the Incident and supporting all associated ongoing investigations. On October 5, 2021, the Unified Command announced that reports from its contracted commercial divers and Remotely Operated Vehicle footage indicated that a 4,000-foot section of the Company's pipeline had been displaced with a maximum lateral movement of approximately 105 feet and that the pipeline had a 13-inch split, running parallel to the pipe. On October 14, 2021, the U.S. Coast Guard announced that it had a high degree of confidence the size of the release was approximately 588 barrels of oil, which is below the previously reported maximum estimate of 3,134 barrels. On October 16, 2021, the U.S. Coast Guard announced that it had identified the Mediterranean Shipping Company (DANIT) as a "vessel of interest" in connection with an anchor-dragging incident, which occurred in close proximity to the Company's pipeline, and that additional vessels of interest continue to be investigated. The cause, timing and details regarding the Incident are currently under investigation and any information regarding the Incident is preliminary. Following the Incident, the Company deployed contractors so that at the height of the Incident response there were over 1,800 personnel working under the guidance and at the direction of the Unified Command to aid in cleanup operations. As of October 14, 2021, all beaches that had been closed following the Incident have reopened. On October 15, 2021, the Unified Command announced that reports from trained oil observers and beach cleanup contractors working for the Unified Command showed significant progress in cleanup operations. On October 18, 2021, the Unified Command stated that segments of beach are recommended for no further clean-up activities. While the Unified Command has significantly reduced the number of personnel conducting remediation activities from the height of the effort, remediation efforts remain ongoing at November 15, 2021. The Company carries customary industry insurance policies, including loss of production income insurance, which it expects will cover a material portion of the total aggregate costs associated with the Incident, including loss of revenue resulting from suspended operations. However, the Company can provide no assurance that its coverage will adequately protect it against liability from all potential consequences, damages and losses related to the Incident. In response to the Incident, all operations have been suspended and the pipeline has been shut-in until the Company receives the required regulatory approvals to begin operations. At present, given that the pipeline to shore is not operational, no operations are underway in the Beta field.

07:14 EST Dynatrace CEO John Van Siclen to retire, Rick McConnell to succeed - Dynatrace (DT) and its board of directors announced that its CEO and director, John Van Siclen, plans to retire effective December 13. Rick McConnell, currently president and GM, Security Technology Group at Akamai Technologies (AKAM), has been appointed as the company's new CEO and director, effective December 13. Van Siclen will remain as a consultant to the company through May 31, 2022 to facilitate the CEO transition. Van Siclen has led Dynatrace since 2008.

07:09 EST Gamida Cell reports Q3 EPS ($1.18), consensus (48c) - "We are committed to advance our programs and bring our important potential therapies to patients as quickly as possible. We are working diligently to respond to the FDA's information requests for omidubicel and GDA-201, and now expect to submit the BLA for omidubicel to the FDA in the first half of 2022 and we hope to promptly address outstanding issues regarding our IND application relating to GDA-201." said Julian Adams, chief executive officer of Gamida Cell. "Additionally, at our recent NK-focused R&D Day, we provided details on our genetically modified NK cell immunotherapy programs leveraging CAR- and CRISPR-mediated strategies against hematologic malignancies and solid tumors. The company remains focused on our goal of bringing patients with cancer potentially curative cell therapies."

07:07 EST L3Harris Technologies receives $125M multi-year contract - L3Harris Technologies received a $125M multi-year contract to produce space electronic warfare systems that safeguard U.S. military operations and warfighters. Under the Meadowlands production program, L3Harris will upgrade 16 Block 10.2 versions of Counter-Communications Systems, or CCS, operating in Peterson Space Force Base, Colorado, Vandenburg Space Force Base, California, Cape Canaveral Space Force Station, Florida, and multiple international locations.

07:05 EST Instil Bio expects cash to fund operating plan into 2023 - As of September 30, 2021, we had $20.4 million in cash and cash equivalents and $495.0 million in marketable securities, compared to $241.7 million in cash and cash equivalents and no investments in marketable securities as of December 31, 2020. The Company expects that its cash, cash equivalents and marketable securities as of September 30, 2021 will enable it to fund its operating plan into 2023.

07:03 EST Aecom launches Digital AECOM - AECOM announced the launch of Digital AECOM, which combines the Company's global digital-focused consulting services, hosted services products to help clients accelerate their digital journeys and achieve better project outcomes, and digital tools to enhance its delivery of core engineering and design services. The branded offer leverages the strengths of the firm's more than 2,000 integrated digital practitioners globally and proven AECOM technology to connect data, projects, and communities.Core Elements of Digital AECOM's Offering: Digital Consulting Services: Digital AECOM's consulting services are delivered by subject matter experts across all regions and markets. These services are focused on assisting asset owner clients make their own digital transformation as they seek to unlock productivity improvements and innovation in their businesses. AECOM's industry-leading knowledge shaped by rich asset management and technical expertise provides a unique and independent perspective of the technology choices facing clients and industry. The Company offers consulting services across four key pillars: digital strategy, digital design and operations, data analytics and artificial intelligence, and digital solutions delivery. Digital Products:: Following several years of investment and successful prototyping, Digital AECOM is launching the first of its global software solutions to market that will augment and reimagine the Company's core design and infrastructure services. Today's launch includes PlanEngageTM, a unique digital tool that streamlines the planning stakeholder engagement process by improving public participation and understanding of the planning process, and PlanSpendTM, which serves as a capital planning platform that helps clients prioritize and manage their most important projects.

07:00 EST Akamai CIO Mani Sundaram to switch roles, Kate Prouty to succeed - Akamai announced that Mani Sundaram, currently Akamai's EVP and chief information officer, or CIO, has been named EVP and general manager of the Security Technology Group, and that Kate Prouty is being promoted to CIO. These changes are effective December 13. Rick McConnell, Akamai's president and current general manager for STG, will be leaving Akamai to become CEO of a public company after transitioning responsibilities to Sundaram.

06:55 EST K92 Mining sees 2021 production 96,000-102,000 oz AuEq - Challenges related to COVID-19 were significantly greater than expected, with COVID-19 mitigation measures directly increasing cash costs of $60 to 80 per ounce and $70 to $90 per ounce gold attributable. COVID-19 also had a notable impact on production, particularly due to staff shortages from increased quarantine requirements and absenteeism. As a result, 2021 guidance is now production of 96,000 and 102,000 oz AuEq, cash costs between $670 and $720 per ounce gold, All-in Sustaining Costs between $920 and $970 per ounce gold, growth capital of $20-25 million and exploration expenditures of $10-13 million. For 2022, we see multiple positive outcomes from recent developments, including: easing of expatriate travel as COVID-19 restrictions are progressively relaxed; COVID-19 vaccination roll-out ramping up on site; entirely new mining front commencing production at Judd Vein System; Stage 2 Expansion plant throughput achieved, with Stage 2A Expansion approved to increase throughput +25%, and; significant focus on resource growth initiatives with Kora infill program for the definitive feasibility study resource estimate completed in Q4 2021.

06:49 EST Descartes Systems says Audio-Technica using foreign trade zone solution - Descartes Systems Group announced that Audio-Technica is using Descartes' foreign trade zone solution to accelerate customs clearance, reduce the costs associated with filing customs entries, and eliminate duties on exports from the U.S.

06:42 EST DarioHealth appoints Jerrod Helms to chief commercial officer - DarioHealth announced that the company appointed Jerrod Helms to the newly created role of chief commercial officer, or CCO, to support the rapid expansion of business in the employer, payer, provider and partnership markets that the company has seen over the last quarter and the anticipated acceleration into 2022. Helms will report to Rick Anderson, president and GM North America. Helms brings a wealth of sales leadership experience in the business-to-business health care markets, with a successful track record of selling to employers and health plans. In his role as CCO, Jerrod will be responsible for all Dario sales channels and partnerships. He joins Dario after most recently serving as head of sales at the combined entity of Ginger and Headspace.

06:40 EST Materialise exercises option to acquire Link3D for $33.5M - Materialise has agreed to exercise its option to acquire Link3D Inc., an additive workflow and digital manufacturing software company that supports customers in major manufacturing industries to scale and integrate their AM operations across complex supply chains and IT environments. The transaction, which is subject to conditions that are typical for this type of transaction, is expected to close by the end of the year. Materialise will acquire 100% of the Link3D equity interests for $33.5M. The company said, "Building on the success of its existing additive manufacturing software suite, Materialise has outlined an ambitious cloud-based platform strategy. The Materialise software platform will offer companies cloud-based access to a continuously growing set of digital tools, enabling users to personalize and manage their 3D printing processes and streamline their workflows. The acquisition of Link3D will strengthen and accelerate the creation of the Materialise software platform, particularly for companies that are scaling up their additive manufacturing operations to volume production. By integrating Link3D's additive MES solution with the Materialise Magics software suite into a unified, cloud-based software platform, manufacturers will be able to run and continuously improve the most efficient, repeatable, automated and controlled processes to mass-produce identical or customized products. This process extends beyond the actual 3D printing operations and creates a closer alignment between 3D printing and conventional manufacturing, signaling the removal of the wall between both production environments."

06:38 EST Ares Commercial adds borrowing capacity to support further growth - Ares Commercial Real Estate Corporation announced that it has entered into an agreement to increase its existing Term Loan from $60M to $150less than, reduce the all-in pricing from LIBOR plus 5.75% to an initial fixed rate of 4.50% and extend the initial maturity to November 2026. In addition, the Company announced that it increased the size of its secured revolving facility with City National Bank from $50M to $75M. Collectively, the Term Loan and the CNB Facility will be used to fund new loan originations, increase the investment portfolio, and for other working capital and general corporate purposes.

06:34 EST Trane named to the S&P Dow Jones Sustainability North America Index - Trane Technologies has been named to the S&P Dow Jones Sustainability North America Index for the eleventh consecutive year and also this year appears on the World Index. The company performed in the 95th percentile in the Capital Goods industry in the S&P Global Corporate Sustainability Assessment

06:33 EST Adagio Therapeutics expects cash to support operating plans into 2023 - As of September 30, 2021, Adagio had cash, cash equivalents and marketable securities of $666.3 million, which are expected to support the company's current operating plans into 2023.

06:16 EST BiomX sees cash runway to 1H24 - Cash balance and short-term deposits as of September 30, 2021, were $68.3 million, compared to $57.1 million as of December 31, 2020. The increase was primarily due to net cash provided by financing activities partially offset with net cash used in operating activities. During the third quarter, the Company completed a $15 million registered direct equity financing and debt financing agreement of up to $30 million. Based upon the BiomX's new strategic focus on its cystic fibrosis and atopic dermatitis programs, the Company now expects its existing cash, cash equivalents and short-term deposits to be sufficient to fund the Company's current operating plan until the end of 2023. Additional tranches that will become available to the Company under its venture debt facility upon satisfaction of certain specified milestones can further extend the Company's cash runway to the first half of 2024.

06:13 EST Freyr Battery announces strategic mandates, milestones for next 18 months - FREYR is focused on advancing the following strategic mandates and milestones over the next 18 months: Grow conditional offtake commitments and pipeline of commercial opportunities across all market segments to support further capacity expansion. Proceed to FID on combined Gigafactories 1 and 2 at Mo I Rana in 1H 2022 and commence operations at FREYR's Customer Qualification Plant in 2H 2022. Accelerate additional Gigafactory developments in Norway, the U.S. and Finland to concept selection and eventual FIDs. Formalize further agreements with supply chain partners to advance operational and commercial progress and support decarbonisation of supply chain Accelerate evaluation of debt capital solutions to fund FREYR's strategic expansion of Gigafactories 1 and 2

06:10 EST GDS Holdings acquires land in Indonesia for data center development - GDS Holdings announced that it has entered into a definitive agreement to acquire greenfield land in Nongsa Digital Park, located in Batam, Indonesia, approximately 25 kms from Singapore. GDS plans to construct two new data center buildings on the site, comprising a total net floor area of approximately 10,000 sqm and 28 MW of total IT power capacity. GDS expects to secure a supply of renewable energy to support the data center site. The Indonesian Government has deemed Nongsa Digital Park a Special Economic Zone and Indonesia President Joko Widodo described it as the country's "digital bridge" to the rest of the world. The Company's development in Nongsa Digital Park will complement its existing project in Nusajaya Tech Park, Johor Bahru, Malaysia forming a strong core for its "Singapore Plus" strategy in the region. The Company has recently entered into a strategic cooperation agreement with a major Chinese cloud service provider to support its international expansion, pursuant to which GDS will be prioritized as its data center provider in the region. The strategic cooperation extends the mutual trust between GDS and the customer from China to Southeast Asia, providing strong impetus for the success of the Company's regional strategy.

06:08 EST Immuron says USU expects enrollment data of April 2022 Travelers' Diarrhea study - Immuron is pleased to provide shareholders and the market with an update on the planned clinical trial program to evaluate the efficacy of Travelan and two other non-antibiotic OTC products in Travelers' Diarrhea sponsored by the Uniformed Services University of the Health Sciences. USU have initiated the manufacturing campaign to produce the first batches of investigational medical products in November 2021 to support the planned clinical trial program to evaluate the efficacy of Travelan and two other dietary supplement products in Travelers' Diarrhea. USU are anticipating an enrollment start date of April 2022 for the planned clinical trial and are hoping to complete enrollment in approximately 18 months. USU's Infectious Diseases Clinical Research Program, the UK Ministry of Defense and the New York City Travel Clinic are jointly planning to conduct the randomized clinical trial to evaluate the efficacy of three nutraceutical products for TD and inform strategies for Defense Force Health Protection. The P4TD study is a randomized, double-blind, placebo controlled multicenter clinical trial designed to evaluate the effectiveness of 3 commercially available nutraceuticals: A prebiotic, a probiotic and IMM-124E passive immunoprophylaxis verses a placebo, for prophylaxis during deployment or travel to a high-TD risk region. All study participants will be randomized to one of the three active products or placebo.

06:06 EST Kirkland Lake Gold's merger with Agnico Eagle recommended by Glass Lewis - Kirkland Lake Gold (KL) announced that Glass, Lewis has become the second independent proxy advisory firm to recommend that the company's shareholders vote for the merger of equals with Agnico Eagle Mines (AEM) by way of a plan of arrangement. Glass Lewis' endorsement follows a favourable report from ISS. On September 28, Kirkland Lake Gold and Agnico Eagle entered into a merger agreement pursuant to which Agnico Eagle will acquire all of the issued and outstanding common shares of Kirkland Lake Gold on the basis of 0.7935 of an Agnico Eagle common share for each Kirkland Lake Gold common share held. Upon completion, existing Kirkland Lake Gold and Agnico Eagle shareholders are expected to own approximately 46% and 54% of the outstanding shares of the pro forma company, respectively. Glass Lewis noted:"Taken collectively, then, we believe there is adequate cause for investors to conclude the proposed arrangement is a strategically compelling merger of equals resulting from a lengthy and considered review yielding scrip-for-scrip terms reasonably reflective of the relative performance, resources and market value of the two firms involved." Kirkland Lake Gold's special meeting of shareholders in connection with the arrangement will be held online on November 26. Kirkland Lake Gold shareholders of record as of the close of business on October 13, 2021 will be eligible to vote at the Meeting.

05:53 EST Capital Senior Living changes name to Sonida Senior Living, switches symbol - Capital Senior Living (CSU) announced that it has officially changed its name to Sonida Senior Living. The Company's common stock will continue trading on the New York Stock Exchange under its new ticker symbol (SNDA). The company timed the name change to coincide with the recently closed investment from Conversant Capital that raised a total of $154.8M, including aggregate gross proceeds of approximately $34M from the common stock rights offering.

05:44 EST Boeing announces DHL order for nine more 767-300s - DHL Express and Boeing announced that the logistics company placed a firm order for nine more 767-300 Boeing Converted Freighters, or BCF. Representing their largest single 767-300BCF order to date, the additional freighters will help expand DHL's long-haul intercontinental fleet in response to increased global demand for cargo capacity. DHL has taken delivery of seven of a batch of eight 767-300BCF, that have been leased to DHL partner airlines in the Middle East and Latin America to support its expanding regional networks.

05:39 EST The9 NFT platform signs exclusive license agreement with Christian McCaffrey - The9 announced that its new NFT community and trading platform NFTSTAR has signed an exclusive license agreement with the American Football star, Christian McCaffrey. NFTSTAR will exclusively develop, sell and trade NFT collections created and developed with McCaffrey. McCaffrey will work with NFTSTAR's creative team and artists to develop digital collections including video, animation and other digital artworks, which will creatively capture the highlights of McCaffrey's professional career and growth.

05:32 EST Autoliv, SSAB collaborate to produce fossil-free steel components - Autoliv and global steel company SSAB, have initiated a collaboration to research and develop fossil-free steel components for automotive safety products, such as airbags and seatbelts. A new process aims to replace coking coal, traditionally needed for ore-based steelmaking, with hydrogen. The result will be unique: the world's first fossil-free steelmaking technology, with no carbon footprint.

05:27 EST Amazon announces black Friday deals to be available on November 25 - Amazon announced that more Black Friday deals than ever before will be available starting on Thursday, November 25. Customers will be able to shop deals with discounts on products and items, including new gadgets and electronics from Samsung; toys and baby essentials from Mattel and Cybex gb Pockit; home and kitchen items from Instant Pot; seasonal fashion finds, including rag & bone from Shopbop; and beauty favorites from Sunday Riley, OPI, Color Wow, and many more. In addition, customers can find thousands of deals from Amazon's independent selling partners, most of which are small and medium-sized businesses, throughout Amazon's 48-hour Black Friday event, including deals from women-owned, military family-owned, and Black-owned businesses.

05:22 EST AiHuiShou changes name to ATRenew - ATRenew announced that it has changed its name from "AiHuiShou International" to "ATRenew" effective immediately. The change of name was approved by the company's shareholders at the extraordinary general meeting held on November 15. The American depositary shares, every three representing two Class A ordinary shares, of the company, par value $0.001 per share, will begin trading under the new corporate name on November 15. The name change has no effect on the company's ticker symbol, which will remain (RERE).

05:13 EST Tarena, buyer group terminate plan of merger - Tarena announced that the company and the buyer group consisting of Han Shaoyun, Ascendent Capital Partners, Kidedu Holdings, Kidarena Merger Sub, a wholly owned subsidiary of parent and Kidtech, a wholly owned subsidiary of Han Shaoyun, have mutually agreed to terminate the previously announced agreement and plan of merger, dated April 30. All parties have entered into a Termination and settlement agreement with respect to the mutual termination. The company and the buyer group parties were in disagreement on specific terms and conditions within the merger agreement. Subsequently, the company delivered a written notice to the buyer group parties on September 30, informing them of the company's intention to terminate the merger agreement. In order to resolve such differences, the parties engaged in discussions to proactively explore solutions. Ultimately, all parties mutually agreed to terminate the merger agreement and release the parties' obligations thereunder subject to the terms of the Termination Agreement. Pursuant to the termination agreement, in connection with the settlement and mutual termination, the buyer group parties will pay a settlement payment of $3.53M to the company by November 26. The merger agreement will be terminated upon receipt by the company of such payment in full within the aforementioned time period.